BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, Raverdy V, Leteurtre E, Dharancy S, Louvet A, Romon M, Duhamel A, Pattou F, Mathurin P. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Gastroenterology. 2015;149:379-88; quiz e15. [PMID: 25917783 DOI: 10.1053/j.gastro.2015.04.014] [Cited by in Crossref: 399] [Cited by in F6Publishing: 339] [Article Influence: 66.5] [Reference Citation Analysis]
Number Citing Articles
1 Neuschwander-Tetri BA. Therapeutic Landscape for NAFLD in 2020. Gastroenterology 2020;158:1984-1998.e3. [PMID: 32061596 DOI: 10.1053/j.gastro.2020.01.051] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 29.0] [Reference Citation Analysis]
2 Selicean S, Wang C, Guixé-Muntet S, Stefanescu H, Kawada N, Gracia-Sancho J. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol Int 2021;15:36-50. [PMID: 33544313 DOI: 10.1007/s12072-021-10135-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yan T, Yan N, Wang P, Xia Y, Hao H, Wang G, Gonzalez FJ. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm Sin B 2020;10:3-18. [PMID: 31993304 DOI: 10.1016/j.apsb.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
4 García-compeán D, Villarreal-pérez JZ, Cavazos MEDLO, Lavalle-gonzalez FJ, Borjas-almaguer OD, Del Cueto-aguilera AN, González-gonzález JA, Treviño-garza C, Huerta-pérez L, Maldonado-garza HJ. Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening? Annals of Hepatology 2020;19:258-64. [DOI: 10.1016/j.aohep.2020.01.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Byrne CD, Targher G. Time to Replace Assessment of Liver Histology With MR-Based Imaging Tests to Assess Efficacy of Interventions for Nonalcoholic Fatty Liver Disease. Gastroenterology 2016;150:7-10. [DOI: 10.1053/j.gastro.2015.11.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
6 Billeter AT, Müller PC, Albrecht T, Roessler S, Löffler M, Lemekhova A, Mehrabi A, Müller-Stich BP, Hoffmann K. Impact of Type 2 Diabetes on Oncologic Outcomes of Hepatocellular Carcinomas in Non-Cirrhotic, Non-alcoholic Steatohepatitis: a Matched-Pair Analysis. J Gastrointest Surg 2021;25:1193-202. [PMID: 32378092 DOI: 10.1007/s11605-020-04628-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Bischoff SC. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr 2019;38:485-521. [PMID: 30712783 DOI: 10.1016/j.clnu.2018.12.022] [Cited by in F6Publishing: 113] [Reference Citation Analysis]
8 Rubino F, Cohen RV, Mingrone G, le Roux CW, Mechanick JI, Arterburn DE, Vidal J, Alberti G, Amiel SA, Batterham RL, Bornstein S, Chamseddine G, Del Prato S, Dixon JB, Eckel RH, Hopkins D, McGowan BM, Pan A, Patel A, Pattou F, Schauer PR, Zimmet PZ, Cummings DE. Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. Lancet Diabetes Endocrinol 2020;8:640-8. [PMID: 32386567 DOI: 10.1016/S2213-8587(20)30157-1] [Cited by in Crossref: 76] [Cited by in F6Publishing: 28] [Article Influence: 76.0] [Reference Citation Analysis]
9 Morris MC, Jung AD, Kim Y, Lee TC, Kaiser TE, Thompson JR, Bari K, Shah SA, Cohen RM, Schauer DP, Smith EP, Diwan TS. Delayed Sleeve Gastrectomy Following Liver Transplantation: A 5-Year Experience. Liver Transpl 2019;25:1673-81. [PMID: 31518478 DOI: 10.1002/lt.25637] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
10 Coccia F, Testa M, Guarisco G, Bonci E, Di Cristofano C, Silecchia G, Leonetti F, Gastaldelli A, Capoccia D. Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity. Endocrine 2020;67:569-78. [PMID: 31858390 DOI: 10.1007/s12020-019-02155-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Tsochatzis EA, Newsome PN. Non-alcoholic fatty liver disease and the interface between primary and secondary care. Lancet Gastroenterol Hepatol 2018;3:509-17. [PMID: 29893235 DOI: 10.1016/S2468-1253(18)30077-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 22] [Article Influence: 25.0] [Reference Citation Analysis]
12 Lassailly G, Caiazzo R, Ntandja-Wandji LC, Gnemmi V, Baud G, Verkindt H, Ningarhari M, Louvet A, Leteurtre E, Raverdy V, Dharancy S, Pattou F, Mathurin P. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020. [PMID: 32553765 DOI: 10.1053/j.gastro.2020.06.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 50.0] [Reference Citation Analysis]
13 Miller A, Jalil S, Hussan H, Kelly S, Hinton A, Hanje J, Michaels A, Conteh L, Black S, Mumtaz K. Apprising the choice of bariatric surgery in patients with compensated cirrhosis with morbid obesity: results of a national analysis. Updates Surg 2021. [PMID: 34351576 DOI: 10.1007/s13304-021-01142-z] [Reference Citation Analysis]
14 Udelsman BV, Corey KE, Lindvall C, Gee DW, Meireles OR, Hutter MM, Chang DC, Witkowski ER. Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery. Surg Obes Relat Dis 2019;15:843-9. [PMID: 31014948 DOI: 10.1016/j.soard.2019.01.035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
15 Barbois S, Stürm N, Aron-Wisnewsky J, Clément K, Bedossa P, Genser L, Hilleret MN, Costentin C, Reche F, Arvieux C, Borel AL. Decision Tree for the Performance of Intraoperative Liver Biopsy During Bariatric Surgery. Obes Surg 2021;31:2641-8. [PMID: 33665755 DOI: 10.1007/s11695-021-05309-w] [Reference Citation Analysis]
16 Fipps DC, Goetze RE, Clark MM, Mara K, Watt KD, Jowsey-Gregoire SG, Heimbach JK, Grothe K. Liver Transplantation After Bariatric Surgery: a Clinical Cohort Study. Obes Surg 2021;31:3700-6. [PMID: 34021883 DOI: 10.1007/s11695-021-05483-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Aron-Wisnewsky J, Clement K, Pépin JL. Nonalcoholic fatty liver disease and obstructive sleep apnea. Metabolism 2016;65:1124-35. [PMID: 27324067 DOI: 10.1016/j.metabol.2016.05.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 11.0] [Reference Citation Analysis]
18 Jamialahmadi T, Nematy M, Jangjoo A, Goshayeshi L, Rezvani R, Ghaffarzadegan K, Nooghabi MJ, Shalchian P, Zangui M, Javid Z, Doaei S, Rajabzadeh F. Measurement of Liver Stiffness with 2D-Shear Wave Elastography (2D-SWE) in Bariatric Surgery Candidates Reveals Acceptable Diagnostic Yield Compared to Liver Biopsy.Obes Surg. 2019;29:2585-2592. [PMID: 31077025 DOI: 10.1007/s11695-019-03889-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
19 Hadefi A, Arvanitakis M, Huberty V, Devière J. Metabolic endoscopy: Today's science-tomorrow's treatment. United European Gastroenterol J 2020;8:685-94. [PMID: 32628898 DOI: 10.1177/2050640620926837] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Angelini G, Castagneto Gissey L, Del Corpo G, Giordano C, Cerbelli B, Severino A, Manco M, Basso N, Birkenfeld AL, Bornstein SR, Genco A, Mingrone G, Casella G. New insight into the mechanisms of ectopic fat deposition improvement after bariatric surgery. Sci Rep 2019;9:17315. [PMID: 31754142 DOI: 10.1038/s41598-019-53702-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
21 Siddiqui MS, Charlton M. Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management. Gastroenterology 2016;150:1849-62. [DOI: 10.1053/j.gastro.2016.02.077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
22 Haas JT, Vonghia L, Mogilenko DA, Verrijken A, Molendi-Coste O, Fleury S, Deprince A, Nikitin A, Woitrain E, Ducrocq-Geoffroy L, Pic S, Derudas B, Dehondt H, Gheeraert C, Van Gaal L, Driessen A, Lefebvre P, Staels B, Francque S, Dombrowicz D. Transcriptional Network Analysis Implicates Altered Hepatic Immune Function in NASH development and resolution. Nat Metab 2019;1:604-14. [PMID: 31701087 DOI: 10.1038/s42255-019-0076-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 16.0] [Reference Citation Analysis]
23 Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021;271:119220. [PMID: 33592199 DOI: 10.1016/j.lfs.2021.119220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Carter D, Dieterich DT, Chang C. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation. Clin Liver Dis 2018;22:213-27. [PMID: 29128058 DOI: 10.1016/j.cld.2017.08.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
25 Lefere S, Onghena L, Vanlander A, van Nieuwenhove Y, Devisscher L, Geerts A. Bariatric surgery and the liver-Mechanisms, benefits, and risks. Obes Rev 2021;22:e13294. [PMID: 34002452 DOI: 10.1111/obr.13294] [Reference Citation Analysis]
26 Russo MF, Lembo E, Mari A, Angelini G, Verrastro O, Nanni G, Pompili M, Raffaelli M, Vecchio FM, Bornstein SR, Mingrone G. Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic Surgery. J Clin Endocrinol Metab 2021;106:750-61. [PMID: 33248441 DOI: 10.1210/clinem/dgaa892] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Idriss R, Hasse J, Wu T, Khan F, Saracino G, McKenna G, Testa G, Trotter J, Klintmalm G, Asrani SK. Impact of Prior Bariatric Surgery on Perioperative Liver Transplant Outcomes. Liver Transpl. 2019;25:217-227. [PMID: 30369002 DOI: 10.1002/lt.25368] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 26.0] [Reference Citation Analysis]
28 Ampuero J, Sánchez-torrijos Y, Aguilera V, Bellido F, Romero-gómez M. Nuevas perspectivas terapéuticas en la esteatohepatitis no alcohólica. Gastroenterología y Hepatología 2018;41:128-42. [DOI: 10.1016/j.gastrohep.2017.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
29 Salman MA, Mikhail HMS, Nafea MA, Sultan AAEA, Elshafey HE, Tourky M, Awad A, Abouelregal TE, Ahmed RA, Ashoush O, AbdelAal AA, Shaaban HE, Atallah M, Yousef M, Salman AA. Impact of laparoscopic sleeve gastrectomy on fibrosis stage in patients with child-A NASH-related cirrhosis. Surg Endosc 2021;35:1269-77. [PMID: 32152677 DOI: 10.1007/s00464-020-07498-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
30 Vily-Petit J, Soty-Roca M, Silva M, Raffin M, Gautier-Stein A, Rajas F, Mithieux G. Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease. Gut 2020;69:2193-202. [PMID: 32205419 DOI: 10.1136/gutjnl-2019-319745] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
31 Qureshi K, Neuschwander-Tetri BA. The molecular basis for current targets of NASH therapies. Expert Opin Investig Drugs 2020;29:151-61. [PMID: 31847612 DOI: 10.1080/13543784.2020.1703949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
32 Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol 2018; 24(30): 3361-3373 [PMID: 30122876 DOI: 10.3748/wjg.v24.i30.3361] [Cited by in CrossRef: 159] [Cited by in F6Publishing: 131] [Article Influence: 53.0] [Reference Citation Analysis]
33 Vuppalanchi R, Chalasani N. Screening Strategies for Nonalcoholic Steatohepatitis in High-Risk Individuals: Trimming Away the Fat. Dig Dis Sci. 2016;61:1790-1792. [PMID: 27010545 DOI: 10.1007/s10620-016-4134-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Gao Y, Tian R, Liu H, Xue H, Zhang R, Han S, Ji L, Huang W, Zhan J, You Y. Research progress on intervention effect and mechanism of protocatechuic acid on nonalcoholic fatty liver disease. Crit Rev Food Sci Nutr 2021;:1-23. [PMID: 34142875 DOI: 10.1080/10408398.2021.1939265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Marchesini G, Mazzella N, Forlani G. Weight Loss for a Healthy Liver. Gastroenterology 2015;149:274-8. [DOI: 10.1053/j.gastro.2015.06.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;43:1109-23. [PMID: 27061197 DOI: 10.1111/apt.13620] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
37 Marchesini G, Petroni ML, Cortez-pinto H. Adipose tissue-associated cancer risk: Is it the fat around the liver, or the fat inside the liver? Journal of Hepatology 2019;71:1073-5. [DOI: 10.1016/j.jhep.2019.09.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
38 Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab 2020;42:101092. [PMID: 33010471 DOI: 10.1016/j.molmet.2020.101092] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 19.0] [Reference Citation Analysis]
39 Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R. Targeting the gut-liver axis in liver disease. J Hepatol. 2017;67:1084-1103. [PMID: 28526488 DOI: 10.1016/j.jhep.2017.05.007] [Cited by in Crossref: 163] [Cited by in F6Publishing: 151] [Article Influence: 40.8] [Reference Citation Analysis]
40 Song Y, Zhang J, Wang H, Guo D, Yuan C, Liu B, Zhong H, Li D, Li Y. A novel immune-related genes signature after bariatric surgery is histologically associated with non-alcoholic fatty liver disease. Adipocyte 2021;10:424-34. [PMID: 34506234 DOI: 10.1080/21623945.2021.1970341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Barbois S, Arvieux C, Leroy V, Reche F, Stürm N, Borel A. Benefit–risk of intraoperative liver biopsy during bariatric surgery: review and perspectives. Surgery for Obesity and Related Diseases 2017;13:1780-6. [DOI: 10.1016/j.soard.2017.07.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
42 Strey CBM, de Carli LA, Fantinelli M, Gobbato SS, Bassols GF, Losekann A, Coral GP. Impact of Diabetes Mellitus and Insulin on Nonalcoholic Fatty Liver Disease in the Morbidly Obese. Ann Hepatol 2018;17:585-91. [PMID: 29893699 DOI: 10.5604/01.3001.0012.0922] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
43 Kalinowski P, Paluszkiewicz R, Ziarkiewicz-Wróblewska B, Wróblewski T, Remiszewski P, Grodzicki M, Krawczyk M. Liver Function in Patients With Nonalcoholic Fatty Liver Disease Randomized to Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy: A Secondary Analysis of a Randomized Clinical Trial. Ann Surg 2017;266:738-45. [PMID: 28767558 DOI: 10.1097/SLA.0000000000002397] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 10.8] [Reference Citation Analysis]
44 Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015;1. [DOI: 10.1038/nrdp.2015.80] [Cited by in Crossref: 302] [Cited by in F6Publishing: 288] [Article Influence: 50.3] [Reference Citation Analysis]
45 Hedjoudje A, Abu Dayyeh BK, Cheskin LJ, Adam A, Neto MG, Badurdeen D, Morales JG, Sartoretto A, Nava GL, Vargas E, Sui Z, Fayad L, Farha J, Khashab MA, Kalloo AN, Alqahtani AR, Thompson CC, Kumbhari V. Efficacy and Safety of Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2020;18:1043-1053.e4. [PMID: 31442601 DOI: 10.1016/j.cgh.2019.08.022] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 21.0] [Reference Citation Analysis]
46 Lanthier N. Les nouveaux traitements de la stéatohépatite non-alcoolique. Nutrition Clinique et Métabolisme 2020;34:216-22. [DOI: 10.1016/j.nupar.2020.04.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Schuppan D, Surabattula R, Wang XY. Determinants of fibrosis progression and regression in NASH. J Hepatol. 2018;68:238-250. [PMID: 29154966 DOI: 10.1016/j.jhep.2017.11.012] [Cited by in Crossref: 160] [Cited by in F6Publishing: 151] [Article Influence: 40.0] [Reference Citation Analysis]
48 Cabré N, Luciano-Mateo F, Fernández-Arroyo S, Baiges-Gayà G, Hernández-Aguilera A, Fibla M, Fernández-Julià R, París M, Sabench F, Castillo DD, Menéndez JA, Camps J, Joven J. Laparoscopic sleeve gastrectomy reverses non-alcoholic fatty liver disease modulating oxidative stress and inflammation. Metabolism 2019;99:81-9. [PMID: 31279739 DOI: 10.1016/j.metabol.2019.07.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
49 Saitta C, Pollicino T, Raimondo G. Obesity and liver cancer. Ann Hepatol 2019;18:810-5. [PMID: 31543467 DOI: 10.1016/j.aohep.2019.07.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
50 Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
51 Yoon JH, Lee JM, Lee KB, Kim D, Kabasawa H, Han JK. Comparison of monoexponential, intravoxel incoherent motion diffusion-weighted imaging and diffusion kurtosis imaging for assessment of hepatic fibrosis. ActaRadiol. 2019;60:1593-1601. [PMID: 30935212 DOI: 10.1177/0284185119840219] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
52 Lazaridis N, Tsochatzis E. Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Review of Gastroenterology & Hepatology 2017;11:357-69. [DOI: 10.1080/17474124.2017.1293523] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
53 Whang E, Liu Y, Kageyama S, Woo SL, Yang J, Lee R, Li Z, Ji H, Chen Y, Kupiec-Weglinski JW. Vertical Sleeve Gastrectomy Attenuates the Progression of Non-Alcoholic Steatohepatitis in Mice on a High-Fat High-Cholesterol Diet. Obes Surg 2019;29:2420-9. [PMID: 30982168 DOI: 10.1007/s11695-019-03860-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Benosman H, Rahmi G, Perrod G, Bruzzi M, Samaha E, Vienne A, Cuenod CA, Chevallier JM, Douard R, Cellier C. Endoscopic Management of Post-bariatric Surgery Fistula: a Tertiary Care Center Experience. OBES SURG 2018;28:3910-5. [DOI: 10.1007/s11695-018-3432-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
55 Doulberis M, Kotronis G, Gialamprinou D, Kountouras J, Katsinelos P. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism 2017;71:182-97. [DOI: 10.1016/j.metabol.2017.03.013] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 16.8] [Reference Citation Analysis]
56 Sanai FM, Abaalkhail F, Hasan F, Farooqi MH, Nahdi NA, Younossi ZM. Management of nonalcoholic fatty liver disease in the Middle East. World J Gastroenterol 2020; 26(25): 3528-3541 [PMID: 32742124 DOI: 10.3748/wjg.v26.i25.3528] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Lisboa QC, Costa SM, Couto CA. Current management of non-alcoholic fatty liver disease. Rev Assoc Med Bras (1992) 2016;62:872-8. [PMID: 28001263 DOI: 10.1590/1806-9282.62.09.872] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
58 Vangoitsenhoven R, Wilson RL, Cherla DV, Tu C, Kashyap SR, Cummings DE, Schauer PR, Aminian A. Presence of Liver Steatosis Is Associated With Greater Diabetes Remission After Gastric Bypass Surgery. Diabetes Care 2021;44:321-5. [PMID: 33323476 DOI: 10.2337/dc20-0150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
59 Wu WK, Chen YH, Lee PC, Yang PJ, Chang CC, Liu KL, Hsu CC, Huang CC, Chuang HL, Sheen LY, Liu CJ, Wu MS. Mining Gut Microbiota From Bariatric Surgery for MAFLD. Front Endocrinol (Lausanne) 2021;12:612946. [PMID: 33897617 DOI: 10.3389/fendo.2021.612946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Rinella ME, Lominadze Z, Loomba R, Charlton M, Neuschwander-Tetri BA, Caldwell SH, Kowdley K, Harrison SA. Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therap Adv Gastroenterol 2016;9:4-12. [PMID: 26770262 DOI: 10.1177/1756283X15611581] [Cited by in Crossref: 38] [Cited by in F6Publishing: 13] [Article Influence: 7.6] [Reference Citation Analysis]
61 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Reference Citation Analysis]
62 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9:65-90. [PMID: 27055256 DOI: 10.1159/000443344] [Cited by in Crossref: 129] [Cited by in F6Publishing: 119] [Article Influence: 25.8] [Reference Citation Analysis]
63 Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH epidemic: A call to action. Metabolism 2021;122:154822. [PMID: 34289945 DOI: 10.1016/j.metabol.2021.154822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Dasgupta D, Nakao Y, Mauer AS, Thompson JM, Sehrawat TS, Liao CY, Krishnan A, Lucien F, Guo Q, Liu M, Xue F, Fukushima M, Katsumi T, Bansal A, Pandey MK, Maiers JL, DeGrado T, Ibrahim SH, Revzin A, Pavelko KD, Barry MA, Kaufman RJ, Malhi H. IRE1A Stimulates Hepatocyte-Derived Extracellular Vesicles That Promote Inflammation in Mice With Steatohepatitis. Gastroenterology 2020;159:1487-1503.e17. [PMID: 32574624 DOI: 10.1053/j.gastro.2020.06.031] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 26.0] [Reference Citation Analysis]
65 Gao Y, Zhang J, Xiao X, Ren Y, Yan X, Yue J, Wang T, Wu Z, Lv Y, Wu R. The Role of Gut Microbiota in Duodenal-Jejunal Bypass Surgery-Induced Improvement of Hepatic Steatosis in HFD-Fed Rats. Front Cell Infect Microbiol 2021;11:640448. [PMID: 33869077 DOI: 10.3389/fcimb.2021.640448] [Reference Citation Analysis]
66 Goldoni MB, Fontes PRO, GuimarÃes MM, Diedrich-Neto JA, Nogueira T, Teixeira UF, Giacomazzi CB, Kiss G, Pioner SR, Rodrigues PD. BYPASS VS. SLEEVE AND ITS EFFECTS IN NON-ALCOHOLIC FATTY LIVER DISEASE: WHAT IS THE BEST TECHNIQUE? Arq Bras Cir Dig 2021;33:e1549. [PMID: 33470379 DOI: 10.1590/0102-672020200003e1549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Duriez M, Jacquet A, Hoet L, Roche S, Bock MD, Rocher C, Haussy G, Vigé X, Bocskei Z, Slavnic T, Martin V, Guillemot JC, Didier M, Kannt A, Orsini C, Mikol V, Fèvre AL. A 3D Human Liver Model of Nonalcoholic Steatohepatitis. J Clin Transl Hepatol 2020;8:359-70. [PMID: 33447518 DOI: 10.14218/JCTH.2020.00015] [Reference Citation Analysis]
68 Santos RD, Valenti L, Romeo S. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis 2019;282:110-20. [PMID: 30731283 DOI: 10.1016/j.atherosclerosis.2019.01.029] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 18.0] [Reference Citation Analysis]
69 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97. [DOI: 10.1016/j.metabol.2018.11.014] [Cited by in Crossref: 165] [Cited by in F6Publishing: 164] [Article Influence: 82.5] [Reference Citation Analysis]
70 Poekes L, Gillard J, Farrell GC, Horsmans Y, Leclercq IA. Activation of brown adipose tissue enhances the efficacy of caloric restriction for treatment of nonalcoholic steatohepatitis. Lab Invest 2019;99:4-16. [PMID: 30258096 DOI: 10.1038/s41374-018-0120-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
71 Uchida D, Takaki A, Adachi T, Okada H. Beneficial and Paradoxical Roles of Anti-Oxidative Nutritional Support for Non-Alcoholic Fatty Liver Disease. Nutrients 2018;10:E977. [PMID: 30060482 DOI: 10.3390/nu10080977] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
72 Radaelli MG, Martucci F, Perra S, Accornero S, Castoldi G, Lattuada G, Manzoni G, Perseghin G. NAFLD/NASH in patients with type 2 diabetes and related treatment options. J Endocrinol Invest 2018;41:509-21. [DOI: 10.1007/s40618-017-0799-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
73 Bardou-Jacquet E, Morandeau E, Anderson GJ, Ramm GA, Ramm LE, Morcet J, Bouzille G, Dixon J, Clouston AD, Lainé F, Turlin B, Powell LW, Deugnier YM. Regression of Fibrosis Stage With Treatment Reduces Long-Term Risk of Liver Cancer in Patients With Hemochromatosis Caused by Mutation in HFE. Clin Gastroenterol Hepatol 2020;18:1851-7. [PMID: 31622736 DOI: 10.1016/j.cgh.2019.10.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
74 Nikai H, Ishida K, Umemura A, Baba S, Nitta H, Sugai T, Sasaki A. Effects of Laparoscopic Sleeve Gastrectomy on Non-Alcoholic Steatohepatitis and Liver Fibrosis in Japanese Patients with Severe Obesity. Obes Surg 2020;30:2579-87. [PMID: 32124215 DOI: 10.1007/s11695-020-04515-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
75 Ooi GJ, Burton PR, Doyle L, Wentworth JM, Bhathal PS, Sikaris K, Cowley MA, Roberts SK, Kemp W, O’brien PE, Brown WA. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese. OBES SURG 2017;27:115-25. [DOI: 10.1007/s11695-016-2246-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
76 Panunzi S, Maltese S, Verrastro O, Labbate L, De Gaetano A, Pompili M, Capristo E, Bornstein SR, Mingrone G. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. Diabetes Obes Metab. 2021;23:980-990. [PMID: 33368954 DOI: 10.1111/dom.14304] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
77 Lassailly G, Caiazzo R, Pattou F, Mathurin P. Perspectives on Treatment for Nonalcoholic Steatohepatitis. Gastroenterology. 2016;150:1835-1848. [PMID: 26971824 DOI: 10.1053/j.gastro.2016.03.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 10.2] [Reference Citation Analysis]
78 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Steggerda JA, Mahendraraj K, Todo T, Noureddin M. Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge. World J Gastroenterol 2020; 26(28): 4018-4035 [PMID: 32821068 DOI: 10.3748/wjg.v26.i28.4018] [Reference Citation Analysis]
80 Ntandja Wandji LC, Gnemmi V, Mathurin P, Louvet A. Combined alcoholic and non-alcoholic steatohepatitis. JHEP Rep 2020;2:100101. [PMID: 32514497 DOI: 10.1016/j.jhepr.2020.100101] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
81 Stefan N. [New pharmacological treatment options for nonalcoholic fatty liver disease]. Internist (Berl) 2020;61:759-65. [PMID: 32409850 DOI: 10.1007/s00108-020-00801-4] [Reference Citation Analysis]
82 Motamedi MAK, Rakhshani N, Khalaj A, Barzin M. Biopsy-proven progressive fatty liver disease nine months post mini-gastric bypass surgery: A case study. Int J Surg Case Rep 2017;39:168-71. [PMID: 28846948 DOI: 10.1016/j.ijscr.2017.07.062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
83 Rodrigues RM, Guan Y, Gao B. Targeting adipose tissue to tackle NASH: SPARCL1 as an emerging player. J Clin Invest 2021;131:e153640. [PMID: 34651578 DOI: 10.1172/JCI153640] [Reference Citation Analysis]
84 Caravatto PP, Cohen R. The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement. Curr Atheroscler Rep. 2017;19:45. [PMID: 28986720 DOI: 10.1007/s11883-017-0681-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
85 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
86 Sanguankeo A. Comment on: gastric bypass specifically impairs liver parameters as compared with sleeve gastrectomy, independently of evolution of metabolic disorders. Surg Obes Relat Dis 2019;15:513. [PMID: 30709749 DOI: 10.1016/j.soard.2019.01.006] [Reference Citation Analysis]
87 Xia MF, Bian H, Gao X. NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. Front Pharmacol. 2019;10:877. [PMID: 31447675 DOI: 10.3389/fphar.2019.00877] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
88 Rachakonda V, Wills R, Delany JP, Kershaw EE, Behari J. Differential Impact of Weight Loss on Nonalcoholic Fatty Liver Resolution in a North American Cohort with Obesity: NAFLD Resolution with Weight Loss. Obesity 2017;25:1360-8. [DOI: 10.1002/oby.21890] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
89 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia MA, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera JA, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera MF, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio JA, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez JL, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila JF, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco JA. The Mexican consensus on nonalcoholic fatty liver disease.Rev Gastroenterol Mex (Engl Ed). 2019;84:69-99. [PMID: 30711302 DOI: 10.1016/j.rgmx.2018.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
90 Pomenti S, Mehta S, Guo A, Wattacheril J. Bariatric Surgery in the Peritransplant Period. Clin Liver Dis (Hoboken) 2021;17:282-91. [PMID: 33968390 DOI: 10.1002/cld.1052] [Reference Citation Analysis]
91 Hunter H, de Gracia Hahn D, Duret A, Im YR, Cheah Q, Dong J, Fairey M, Hjalmarsson C, Li A, Lim HK, McKeown L, Mitrofan CG, Rao R, Utukuri M, Rowe IA, Mann JP. Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver. Elife 2020;9:e56573. [PMID: 33063664 DOI: 10.7554/eLife.56573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
92 Huang TD, Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management. Intern Med J 2020;50:1038-47. [PMID: 31760676 DOI: 10.1111/imj.14709] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 27.0] [Reference Citation Analysis]
93 Perazzo H, Dufour JF. The therapeutic landscape of non-alcoholic steatohepatitis. Liver Int. 2017;37:634-647. [PMID: 27727520 DOI: 10.1111/liv.13270] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
94 Hsu CC, Ness E, Kowdley KV. Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. Adv Nutr. 2017;8:253-265. [PMID: 28298270 DOI: 10.3945/an.116.013730] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
95 Arnouk J, Rachakonda VP, Jaiyeola D, Behari J. Differential Outcomes and Clinical Challenges of NAFLD With Extreme Obesity. Hepatol Commun 2020;4:1419-29. [PMID: 33024913 DOI: 10.1002/hep4.1572] [Reference Citation Analysis]
96 Uehara D, Seki Y, Kakizaki S, Horiguchi N, Tojima H, Yamazaki Y, Sato K, Yamada M, Uraoka T, Kasama K. Long-term Results of Bariatric Surgery for Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis Treatment in Morbidly Obese Japanese Patients. OBES SURG 2019;29:1195-201. [DOI: 10.1007/s11695-018-03641-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
97 Mehal WZ. We are not in Kansas anymore: The unfamiliar landscape of NASH. Hepatology 2016;63:682-4. [PMID: 26567082 DOI: 10.1002/hep.28348] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
98 Do A, Kuszewski EJ, Langberg KA, Mehal WZ. Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. Hepatology 2019;70:1443-56. [PMID: 30991446 DOI: 10.1002/hep.30658] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
99 Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 2020;111S:154299. [PMID: 32569680 DOI: 10.1016/j.metabol.2020.154299] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 17.0] [Reference Citation Analysis]
100 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32-42. [PMID: 27729660 DOI: 10.1038/nrgastro.2016.147] [Cited by in Crossref: 329] [Cited by in F6Publishing: 309] [Article Influence: 65.8] [Reference Citation Analysis]
101 Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH Epidemic: A Call to Action. Gastroenterology 2021;161:1030-1042.e8. [PMID: 34416976 DOI: 10.1053/j.gastro.2021.04.074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
102 Patel V, Joharapurkar A, Kshirsagar S, Patel M, Sutariya B, Patel H, Pandey D, Patel D, Ranvir R, Kadam S, Bahekar R, Jain M. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease. Can J Physiol Pharmacol. 2018;96:587-596. [PMID: 29406832 DOI: 10.1139/cjpp-2017-0683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
103 Murakami E, Nakahara T, Hiramatsu A, Morio K, Fujino H, Yamauchi M, Kawaoka T, Tsuge M, Imamura M, Aikata H, Fudeyasu K, Nakashima Y, Iwaki D, Jodai D, Ohigashi T, Nishimura Y, Minamoto Y, Nagao A, Yoneda M, Saeki Y, Tanabe K, Ohdan H, Chayama K. Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients. Medicine (Baltimore) 2021;100:e26436. [PMID: 34190166 DOI: 10.1097/MD.0000000000026436] [Reference Citation Analysis]
104 Talavera-Urquijo E, Beisani M, Balibrea JM, Alverdy JC. Is bariatric surgery resolving NAFLD via microbiota-mediated bile acid ratio reversal? A comprehensive review. Surg Obes Relat Dis 2020;16:1361-9. [PMID: 32336663 DOI: 10.1016/j.soard.2020.03.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
105 Brown GT, Kleiner DE. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism 2016;65:1080-6. [PMID: 26775559 DOI: 10.1016/j.metabol.2015.11.008] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 15.3] [Reference Citation Analysis]
106 Bettini S, Bordigato E, Milan G, Dal Pra' C, Favaretto F, Belligoli A, Sanna M, Serra R, Foletto M, Prevedello L, Busetto L, Fassina G, Vettor R, Fabris R. SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy. Obes Facts 2019;12:291-306. [PMID: 31104052 DOI: 10.1159/000499717] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Dinani A, Sanyal A. Nonalcoholic fatty liver disease: implications for cardiovascular risk. Cardiovasc Endocrinol 2017;6:62-72. [PMID: 31646122 DOI: 10.1097/XCE.0000000000000126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
108 Boeckmans J, Natale A, Rombaut M, Buyl K, Rogiers V, De Kock J, Vanhaecke T, M Rodrigues R. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. Cells 2019;9:E37. [PMID: 31877771 DOI: 10.3390/cells9010037] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
109 Crudele A, Panera N, Braghini MR, Balsano C, Alisi A. The pharmacological treatment of nonalcoholic fatty liver disease in children. Expert Rev Clin Pharmacol 2020;13:1219-27. [PMID: 32981386 DOI: 10.1080/17512433.2020.1829468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Liebe R, Esposito I, Bock HH, Vom Dahl S, Stindt J, Baumann U, Luedde T, Keitel V. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol 2021;74:1455-71. [PMID: 33577920 DOI: 10.1016/j.jhep.2021.01.045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
111 Arrese M, Barrera F, Triantafilo N, Arab JP. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Review of Gastroenterology & Hepatology 2019;13:849-66. [DOI: 10.1080/17474124.2019.1649981] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
112 Marino L, Jornayvaz FR. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21(39): 11053-11076 [PMID: 26494962 DOI: 10.3748/wjg.v21.i39.11053] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
113 Kheirvari M, Dadkhah Nikroo N, Jaafarinejad H, Farsimadan M, Eshghjoo S, Hosseini S, Anbara T. The advantages and disadvantages of sleeve gastrectomy; clinical laboratory to bedside review. Heliyon 2020;6:e03496. [PMID: 32154399 DOI: 10.1016/j.heliyon.2020.e03496] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
114 Seymour KA, Abdelmalek MF. The role of bariatric surgery in the management of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2021;37:208-15. [PMID: 33769376 DOI: 10.1097/MOG.0000000000000721] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Weinberg EM, Trinh HN, Firpi RJ, Bhamidimarri KR, Klein S, Durlam J, Watkins S, Reddy KR, Weiss M, Zink RC, Lok AS. Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases. Clin Gastroenterol Hepatol 2021;19:996-1008.e6. [PMID: 32629123 DOI: 10.1016/j.cgh.2020.06.066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
116 Lemoinne S, Friedman SL. New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases. Curr Opin Pharmacol 2019;49:60-70. [PMID: 31590120 DOI: 10.1016/j.coph.2019.09.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
117 Rustgi VK, Li Y, Gupta K, Minacapelli CD, Bhurwal A, Catalano C, Elsaid MI. Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity. Gastroenterology 2021;161:171-184.e10. [PMID: 33744305 DOI: 10.1053/j.gastro.2021.03.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
118 Brill MJ, Välitalo PA, Darwich AS, van Ramshorst B, van Dongen HP, Rostami-Hodjegan A, Danhof M, Knibbe CA. Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients. CPT Pharmacometrics Syst Pharmacol 2016;5:20-30. [PMID: 26844012 DOI: 10.1002/psp4.12048] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
119 Bischoff SC, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Plauth M. ESPEN practical guideline: Clinical nutrition in liver disease. Clin Nutr 2020;39:3533-62. [PMID: 33213977 DOI: 10.1016/j.clnu.2020.09.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
120 Bravo-san Pedro JM, Sica V, Martins I, Pol J, Loos F, Maiuri MC, Durand S, Bossut N, Aprahamian F, Anagnostopoulos G, Niso-santano M, Aranda F, Ramírez-pardo I, Lallement J, Denom J, Boedec E, Gorwood P, Ramoz N, Clément K, Pelloux V, Rohia A, Pattou F, Raverdy V, Caiazzo R, Denis RG, Boya P, Galluzzi L, Madeo F, Migrenne-li S, Cruciani-guglielmacci C, Tavernarakis N, López-otín C, Magnan C, Kroemer G. Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity. Cell Metabolism 2019;30:754-767.e9. [DOI: 10.1016/j.cmet.2019.07.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
121 Ludwig DR, Fraum TJ, Ballard DH, Narra VR, Shetty AS. Imaging Biomarkers of Hepatic Fibrosis: Reliability and Accuracy of Hepatic Periportal Space Widening and Other Morphologic Features on MRI. AJR Am J Roentgenol 2021;216:1229-39. [PMID: 33729883 DOI: 10.2214/AJR.20.23099] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Lambrecht J, van Grunsven LA, Tacke F. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Expert Opin Pharmacother 2020;21:1637-50. [PMID: 32543284 DOI: 10.1080/14656566.2020.1774553] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
123 Devasthale P, Cheng D. Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH). J Med Chem 2018;61:9879-88. [PMID: 29986142 DOI: 10.1021/acs.jmedchem.8b00864] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
124 Patel YA, Gifford EJ, Glass LM, McNeil R, Turner MJ, Han B, Provenzale D, Choi SS, Moylan CA, Hunt CM. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration. Aliment Pharmacol Ther 2018;47:268-78. [PMID: 29115682 DOI: 10.1111/apt.14411] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
125 Mechanick JI, Apovian C, Brethauer S, Timothy Garvey W, Joffe AM, Kim J, Kushner RF, Lindquist R, Pessah-Pollack R, Seger J, Urman RD, Adams S, Cleek JB, Correa R, Figaro MK, Flanders K, Grams J, Hurley DL, Kothari S, Seger MV, Still CD. Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures - 2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Obesity (Silver Spring) 2020;28:O1-O58. [PMID: 32202076 DOI: 10.1002/oby.22719] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 44.0] [Reference Citation Analysis]
126 Martínez-Montoro JI, Kuchay MS, Balaguer-Román A, Martínez-Sánchez MA, Frutos MD, Fernández-García JC, Ramos-Molina B. Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery. Obes Rev 2021;:e13367. [PMID: 34729904 DOI: 10.1111/obr.13367] [Reference Citation Analysis]
127 Barb D, Portillo-Sanchez P, Cusi K. Pharmacological management of nonalcoholic fatty liver disease. Metabolism. 2016;65:1183-1195. [PMID: 27301803 DOI: 10.1016/j.metabol.2016.04.004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 12.6] [Reference Citation Analysis]
128 Sinclair P, Brennan DJ, le Roux CW. Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer. Nat Rev Gastroenterol Hepatol 2018;15:606-24. [PMID: 30181611 DOI: 10.1038/s41575-018-0057-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
129 Schwenger KJ, Fischer SE, Jackson T, Okrainec A, Allard JP. In nonalcoholic fatty liver disease, Roux-en-Y gastric bypass improves liver histology while persistent disease is associated with lower improvements in waist circumference and glycemic control. Surgery for Obesity and Related Diseases 2018;14:1233-9. [DOI: 10.1016/j.soard.2018.06.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
130 Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(39): 5919-5943 [PMID: 33132645 DOI: 10.3748/wjg.v26.i39.5919] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
131 Pratt JSA, Browne A, Browne NT, Bruzoni M, Cohen M, Desai A, Inge T, Linden BC, Mattar SG, Michalsky M, Podkameni D, Reichard KW, Stanford FC, Zeller MH, Zitsman J. ASMBS pediatric metabolic and bariatric surgery guidelines, 2018. Surg Obes Relat Dis 2018;14:882-901. [PMID: 30077361 DOI: 10.1016/j.soard.2018.03.019] [Cited by in Crossref: 150] [Cited by in F6Publishing: 119] [Article Influence: 50.0] [Reference Citation Analysis]
132 Schneck AS, Anty R, Patouraux S, Bonnafous S, Rousseau D, Lebeaupin C, Bailly-Maitre B, Sans A, Tran A, Gugenheim J, Iannelli A, Gual P. Roux-En Y Gastric Bypass Results in Long-Term Remission of Hepatocyte Apoptosis and Hepatic Histological Features of Non-alcoholic Steatohepatitis. Front Physiol. 2016;7:344. [PMID: 27594839 DOI: 10.3389/fphys.2016.00344] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
133 Lo RC, Kim H. Histopathological evaluation of liver fibrosis and cirrhosis regression. Clin Mol Hepatol. 2017;23:302-307. [PMID: 29281870 DOI: 10.3350/cmh.2017.0078] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 10.0] [Reference Citation Analysis]
134 Marušić M, Paić M, Knobloch M, Liberati Pršo AM. NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. Can J Gastroenterol Hepatol 2021;2021:6613827. [PMID: 33681089 DOI: 10.1155/2021/6613827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
135 Billeter AT, Müller-Stich BP. [Metabolic surgery]. Chirurg 2019;90:157-70. [PMID: 30734078 DOI: 10.1007/s00104-018-0786-z] [Reference Citation Analysis]
136 Goossens N, Hoshida Y, Song WM, Jung M, Morel P, Nakagawa S, Zhang B, Frossard JL, Spahr L, Friedman SL, Negro F, Rubbia-Brandt L, Giostra E. Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. Clin Gastroenterol Hepatol. 2016;14:1619-1628. [PMID: 26492845 DOI: 10.1016/j.cgh.2015.10.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
137 Wang JZ, Cao HX, Chen JN, Pan Q. PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease. World J Clin Cases 2018; 6(8): 167-175 [PMID: 30148144 DOI: 10.12998/wjcc.v6.i8.167] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
138 Jeznach-Steinhagen A, Ostrowska J, Czerwonogrodzka-Senczyna A, Boniecka I, Shahnazaryan U, Kuryłowicz A. Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease. Medicina (Kaunas) 2019;55:E166. [PMID: 31137547 DOI: 10.3390/medicina55050166] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
139 Abbassi Z, Orci L, Meyer J, Sgardello SD, Goossens N, Rubbia-Brandt L, Spahr L, Buchs NC, Mönig SP, Toso C, Hagen ME, Jung MK. Impact of Nonalcoholic Steatohepatitis on the Outcome of Patients Undergoing Roux-en-Y Gastric Bypass Surgery: a Propensity Score-Matched Analysis. Obes Surg 2021. [PMID: 34546514 DOI: 10.1007/s11695-021-05642-0] [Reference Citation Analysis]
140 Xu L, Lu W, Li P, Shen F, Mi Y, Fan J. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B. Digestive and Liver Disease 2017;49:910-7. [DOI: 10.1016/j.dld.2017.03.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
141 Ni Y, Zhuge F, Nagashimada M, Ota T. Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis. Nutrients. 2016;8:pii: E391. [PMID: 27347998 DOI: 10.3390/nu8070391] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 8.8] [Reference Citation Analysis]
142 Spearman CW, Afihene M, Betiku O, Bobat B, Cunha L, Kassianides C, Katsidzira L, Mekonnen HD, Ocama P, Ojo O, Paruk I, Tzeuton C, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol 2021;6:1036-46. [PMID: 34508671 DOI: 10.1016/S2468-1253(21)00275-2] [Reference Citation Analysis]
143 Mahady SE, Adams LA. Burden of non-alcoholic fatty liver disease in Australia: Burden of fatty liver in Australia. Journal of Gastroenterology and Hepatology 2018;33:1-11. [DOI: 10.1111/jgh.14270] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
144 Lytle KA, Jump DB. Is Western Diet-Induced Nonalcoholic Steatohepatitis in Ldlr-/- Mice Reversible? PLoS One 2016;11:e0146942. [PMID: 26761430 DOI: 10.1371/journal.pone.0146942] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
145 Verzijl CRC, Van De Peppel IP, Struik D, Jonker JW. Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis. Expert Opin Investig Drugs. 2020;29:125-133. [PMID: 31899984 DOI: 10.1080/13543784.2020.1708898] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
146 Bonsembiante L, Targher G, Maffeis C. Non-alcoholic fatty liver disease in obese children and adolescents: a role for nutrition? Eur J Clin Nutr 2021. [PMID: 34006994 DOI: 10.1038/s41430-021-00928-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
147 Huang HH, Lee WJ, Chen SC, Chen TF, Lee SD, Chen CY. Bile Acid and Fibroblast Growth Factor 19 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Sleeve Gastrectomy. J Clin Med. 2019;8:pii: E815. [PMID: 31181641 DOI: 10.3390/jcm8060815] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
148 Gevers TJG, Marcel Spanier BW, Veendrick PB, Vrolijk JM. Regression of hepatocellular adenoma after bariatric surgery in severe obese patients. Liver Int 2018;38:2134-6. [PMID: 30025198 DOI: 10.1111/liv.13934] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
149 Ruiz-Tovar J, Zubiaga L. Validation of biochemical scores for liver steatosis before and 1 year after sleeve gastrectomy. Surg Obes Relat Dis 2019;15:1447-53. [PMID: 31204247 DOI: 10.1016/j.soard.2019.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
150 Chao CY, Battat R, Al Khoury A, Restellini S, Sebastiani G, Bessissow T. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. World J Gastroenterol 2016; 22(34): 7727-7734 [PMID: 27678354 DOI: 10.3748/wjg.v22.i34.7727] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
151 Billeter AT, de la Garza Herrera JR, Scheurlen KM, Nickel F, Billmann F, Müller-Stich BP. MANAGEMENT OF ENDOCRINE DISEASE: Which metabolic procedure? Comparing outcomes in sleeve gastrectomy and Roux-en Y gastric bypass. Eur J Endocrinol 2018;179:R77-93. [PMID: 29764908 DOI: 10.1530/EJE-18-0009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
152 Samji NS, Verma R, Satapathy SK. Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective. J Clin Exp Hepatol 2019;9:497-505. [PMID: 31516266 DOI: 10.1016/j.jceh.2019.05.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
153 Spengler EK, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc 2015;90:1233-46. [PMID: 26219858 DOI: 10.1016/j.mayocp.2015.06.013] [Cited by in Crossref: 127] [Cited by in F6Publishing: 112] [Article Influence: 21.2] [Reference Citation Analysis]
154 Nascimbeni F, Ballestri S, Machado MV, Mantovani A, Cortez-pinto H, Targher G, Lonardo A. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Review of Gastroenterology & Hepatology 2018;12:351-67. [DOI: 10.1080/17474124.2018.1415756] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
155 Crespo M, Lappe S, Feldstein AE, Alkhouri N. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. Metabolism 2016;65:1161-71. [DOI: 10.1016/j.metabol.2016.01.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
156 Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:948-963. [PMID: 30819364 DOI: 10.1016/j.jacc.2018.11.050] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 80.0] [Reference Citation Analysis]
157 Lee Y, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, Anvari M, Hong D. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019;17:1040-1060.e11. [PMID: 30326299 DOI: 10.1016/j.cgh.2018.10.017] [Cited by in Crossref: 99] [Cited by in F6Publishing: 90] [Article Influence: 33.0] [Reference Citation Analysis]
158 Mazzini GS, Khoraki J, Dozmorov M, Browning MG, Wijesinghe D, Wolfe L, Gurski RR, Campos GM. Concomitant PPARα and FXR Activation as a Putative Mechanism of NASH Improvement after Gastric Bypass Surgery: a GEO Datasets Analysis. J Gastrointest Surg 2019;23:51-7. [PMID: 30206765 DOI: 10.1007/s11605-018-3938-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
159 Sanyal AJ, Neuschwander-Tetri BA, Tonascia J. End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease. Gastroenterology 2016;150:11-3. [PMID: 26602217 DOI: 10.1053/j.gastro.2015.11.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
160 Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, Hur C. Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. Hepatology. 2017;65:1156-1164. [PMID: 27880977 DOI: 10.1002/hep.28958] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 11.8] [Reference Citation Analysis]
161 Cabré N, Gil M, Amigó N, Luciano-Mateo F, Baiges-Gaya G, Fernández-Arroyo S, Rodríguez-Tomàs E, Hernández-Aguilera A, Castañé H, París M, Sabench F, Del Castillo D, Camps J, Joven J. Laparoscopic sleeve gastrectomy alters 1H-NMR-measured lipoprotein and glycoprotein profile in patients with severe obesity and nonalcoholic fatty liver disease. Sci Rep 2021;11:1343. [PMID: 33446705 DOI: 10.1038/s41598-020-79485-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Woo Baidal JA, Lavine JE. The intersection of nonalcoholic fatty liver disease and obesity. Sci Transl Med 2016;8:323rv1. [PMID: 26819197 DOI: 10.1126/scitranslmed.aad8390] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
163 Yu Y, Cai J, She Z, Li H. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Adv Sci (Weinh). 2019;6:1801585. [PMID: 30828530 DOI: 10.1002/advs.201801585] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
164 Allen AM, Shah VH, Therneau TM, Venkatesh SK, Mounajjed T, Larson JJ, Mara KC, Schulte PJ, Kellogg TA, Kendrick ML, McKenzie TJ, Greiner SM, Li J, Glaser KJ, Wells ML, Chen J, Ehman RL, Yin M. The Role of Three-Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery. Hepatology 2020;71:510-21. [PMID: 30582669 DOI: 10.1002/hep.30483] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 10.5] [Reference Citation Analysis]
165 Chen F, Zhou Y, Wu Z, Li Y, Zhou W, Wang Y. Integrated Analysis of Key Genes and Pathways Involved in Nonalcoholic Steatohepatitis Improvement After Roux-en-Y Gastric Bypass Surgery. Front Endocrinol (Lausanne) 2020;11:611213. [PMID: 33603714 DOI: 10.3389/fendo.2020.611213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
166 Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease.BMJ. 2021;372:m4747. [PMID: 33461969 DOI: 10.1136/bmj.m4747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
167 Povsic M, Oliver L, Jiandani NR, Perry R, Bottomley J. A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH). Pharmacol Res Perspect 2019;7:e00485. [PMID: 31149341 DOI: 10.1002/prp2.485] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
168 Pedersen JS, Rygg MO, Serizawa RR, Kristiansen VB, Albrechtsen NJW, Gluud LL, Madsbad S, Bendtsen F. Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies. J Clin Med 2021;10:3783. [PMID: 34501231 DOI: 10.3390/jcm10173783] [Reference Citation Analysis]
169 Moctezuma-velázquez C. Tratamiento actual de la enfermedad por hígado graso no alcohólico. Revista de Gastroenterología de México 2018;83:125-33. [DOI: 10.1016/j.rgmx.2017.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
170 Lassailly G, Caiazzo R, Mathurin P, Pattou F. Reply. Gastroenterology 2016;150:284-5. [PMID: 26616571 DOI: 10.1053/j.gastro.2015.11.035] [Reference Citation Analysis]
171 Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
172 Yu HH, Hsieh MC, Wu SY, Sy ED, Shan YS. Effects of duodenal-jejunal bypass surgery in ameliorating nonalcoholic steatohepatitis in diet-induced obese rats. Diabetes Metab Syndr Obes 2019;12:149-59. [PMID: 30705600 DOI: 10.2147/DMSO.S190631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
173 Lammers WJ, Tilburg AJV, Apers JA, Wiebolt J. Liver failure caused by prolonged state of malnutrition following bariatric surgery. World J Hepatol 2018; 10(3): 396-399 [PMID: 29599903 DOI: 10.4254/wjh.v10.i3.396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
174 Franchitto A, Carpino G, Alisi A, De Peppo F, Overi D, De Stefanis C, Romito I, De Vito R, Caccamo R, Sonia B, Alessandra S, Mosca A, Alterio A, Onori P, Gaudio E, Nobili V. The Contribution of the Adipose Tissue-Liver Axis in Pediatric Patients with Nonalcoholic Fatty Liver Disease after Laparoscopic Sleeve Gastrectomy. The Journal of Pediatrics 2020;216:117-127.e2. [DOI: 10.1016/j.jpeds.2019.07.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
175 Kakazu E, Mauer AS, Yin M, Malhi H. Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1α-dependent manner. J Lipid Res 2016;57:233-45. [PMID: 26621917 DOI: 10.1194/jlr.M063412] [Cited by in Crossref: 120] [Cited by in F6Publishing: 81] [Article Influence: 20.0] [Reference Citation Analysis]
176 Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15:45. [PMID: 28241825 DOI: 10.1186/s12916-017-0806-8] [Cited by in Crossref: 153] [Cited by in F6Publishing: 137] [Article Influence: 38.3] [Reference Citation Analysis]
177 Bansal MB, Chamroonkul N. Antifibrotics in liver disease: are we getting closer to clinical use? Hepatol Int. 2019;13:25-39. [PMID: 30302735 DOI: 10.1007/s12072-018-9897-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
178 Angelini G, Salinari S, Bertuzzi A, Iaconelli A, Mingrone G. Metabolic surgery improves insulin resistance through the reduction of gut-secreted heat shock proteins. Commun Biol 2018;1:69. [PMID: 30271951 DOI: 10.1038/s42003-018-0069-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
179 Ooi GJ, Earnest A, Kemp WW, Burton PR, Laurie C, Majeed A, Johnson N, McLean C, Roberts SK, Brown WA. Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity. Int J Obes (Lond) 2018;42:1900-11. [PMID: 29463916 DOI: 10.1038/s41366-018-0007-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
180 Nikai H, Sasaki A, Umemura A, Takahashi N, Nitta H, Akasaka R, Kakisaka K, Kuroda H, Ishida K, Takikawa Y. Predictive scoring system for advanced liver fibrosis in Japanese patients with severe obesity. Surg Today 2021;51:1513-20. [PMID: 33829335 DOI: 10.1007/s00595-021-02266-w] [Reference Citation Analysis]
181 Magdy M, Fahmy A, Zaki NI, Mohamed AK. Prophylactic versus therapeutic role of the transplanted CD34+ Umbilical Cord Blood Stem Cells and Wharton Jelly Mesenchymal Stem Cells in early / acute hepatic S. mansoni granulomas reversal in mice; a novel approach. Exp Parasitol 2020;217:107938. [PMID: 32768560 DOI: 10.1016/j.exppara.2020.107938] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
182 Ramos-Molina B, Castellano-Castillo D, Pastor O, Ocaña-Wilhelmi L, Fernández-García D, Romero-Gómez M, Cardona F, Tinahones FJ. A Pilot Study of Serum Sphingomyelin Dynamics in Subjects with Severe Obesity and Non-alcoholic Steatohepatitis after Sleeve Gastrectomy. Obes Surg 2019;29:983-9. [PMID: 30488259 DOI: 10.1007/s11695-018-3612-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
183 Netanel C, Goitein D, Rubin M, Kleinbaum Y, Katsherginsky S, Hermon H, Tsaraf K, Tachlytski I, Herman A, Safran M, Ben-Ari Z. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests. Am J Surg 2021;222:214-9. [PMID: 33309037 DOI: 10.1016/j.amjsurg.2020.11.045] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
184 Kannt A, Madsen AN, Kammermeier C, Elvert R, Klöckener T, Bossart M, Haack T, Evers A, Lorenz K, Hennerici W, Rocher C, Böcskei Z, Guillemot J, Mikol V, Pattou F, Staels B, Wagner M. Incretin combination therapy for the treatment of non‐alcoholic steatohepatitis. Diabetes Obes Metab 2020;22:1328-38. [DOI: 10.1111/dom.14035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
185 Plassmeier L, Hankir MK, Seyfried F. Impact of Excess Body Weight on Postsurgical Complications. Visc Med 2021;37:287-97. [PMID: 34540945 DOI: 10.1159/000517345] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Marchesini G, Petta S, Dalle Grave R. Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice: Marchesini et al. Hepatology 2016;63:2032-43. [DOI: 10.1002/hep.28392] [Cited by in Crossref: 155] [Cited by in F6Publishing: 142] [Article Influence: 31.0] [Reference Citation Analysis]
187 Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016;65:1245-1257. [PMID: 27486010 DOI: 10.1016/j.jhep.2016.07.033] [Cited by in Crossref: 190] [Cited by in F6Publishing: 172] [Article Influence: 38.0] [Reference Citation Analysis]
188 Oberbach A, Schlichting N, Heinrich M, Kullnick Y, Retschlag U, Lehmann S, Khashab MA, Kalloo AN, Kumbhari V. Gastric mucosal devitalization reduces adiposity and improves lipid and glucose metabolism in obese rats. Gastrointest Endosc 2018;87:288-299.e6. [PMID: 28479494 DOI: 10.1016/j.gie.2017.04.038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
189 Cherla DV, Rodriguez NA, Vangoitsenhoven R, Singh T, Mehta N, McCullough AJ, Brethauer SA, Schauer PR, Aminian A. Impact of sleeve gastrectomy and Roux-en-Y gastric bypass on biopsy-proven non-alcoholic fatty liver disease. Surg Endosc 2020;34:2266-72. [PMID: 31359195 DOI: 10.1007/s00464-019-07017-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
190 Klebanoff MJ, Corey KE, Samur S, Choi JG, Kaplan LM, Chhatwal J, Hur C. Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis. JAMA Netw Open 2019;2:e190047. [PMID: 30794300 DOI: 10.1001/jamanetworkopen.2019.0047] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
191 Grattagliano I, Di Ciaula A, Baj J, Molina-Molina E, Shanmugam H, Garruti G, Wang DQ, Portincasa P. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). Methods Mol Biol 2021;2310:201-46. [PMID: 34096005 DOI: 10.1007/978-1-0716-1433-4_12] [Reference Citation Analysis]
192 Zhang C, Cai W, Zhao H, Zhu M, Cui J, Sun Z. Effect of gastric bypass on BMI and lipid metabolism in type 2 diabetes mellitus. Artificial Cells, Nanomedicine, and Biotechnology 2020;48:903-11. [DOI: 10.1080/21691401.2020.1770263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
193 Ciocan D, Lebrun A, Lamouri K, Pourcher G, Voican C, Njiké-nakseu M, Ferretti S, Courie R, Tranchart H, Balian A, Prévot S, Perlemuter G, Dagher I, Naveau S. Adaptation of liver stiffness measurement depth in bariatric surgery candidates with suspected nonalcoholic fatty liver disease: . European Journal of Gastroenterology & Hepatology 2016;28:1014-20. [DOI: 10.1097/meg.0000000000000671] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
194 Aguilar-olivos NE, Almeda-valdes P, Aguilar-salinas CA, Uribe M, Méndez-sánchez N. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. Metabolism 2016;65:1196-207. [DOI: 10.1016/j.metabol.2015.09.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 11.0] [Reference Citation Analysis]
195 Lamos EM, Kristan M, Siamashvili M, Davis SN. Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. Expert Rev Clin Pharmacol 2021;14:837-52. [PMID: 33882758 DOI: 10.1080/17512433.2021.1917374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Kirkpatrick K, Paull-Forney B, Okut H, Schwasinger-Schmidt T. Bariatric Metabolic Surgery Reduced Liver Enzyme Levels in Patients with Non-Alcohol Fatty Liver Disease. Kans J Med 2021;14:209-14. [PMID: 34540134 DOI: 10.17161/kjm.vol1414984] [Reference Citation Analysis]
197 Sivell C. Nonalcoholic Fatty Liver Disease: A Silent Epidemic. Gastroenterol Nurs 2019;42:428-34. [PMID: 31574071 DOI: 10.1097/SGA.0000000000000443] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
198 Pelusi S, Valenti L. Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease. Liver Int 2019;39:250-6. [DOI: 10.1111/liv.13972] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
199 Bauvin P, Delacôte C, Lassailly G, Ntandja Wandji LC, Gnemmi V, Dautrecque F, Louvet A, Caiazzo R, Raverdy V, Leteurtre E, Pattou F, Deuffic-Burban S, Mathurin P. A tool to predict progression of non-alcoholic fatty liver disease in severely obese patients. Liver Int 2021;41:91-100. [PMID: 32881244 DOI: 10.1111/liv.14650] [Reference Citation Analysis]
200 Anty R, Morvan M, Le Corvec M, Canivet CM, Patouraux S, Gugenheim J, Bonnafous S, Bailly-Maitre B, Sire O, Tariel H, Bernard J, Piche T, Loréal O, Aron-Wisnewsky J, Clément K, Tran A, Iannelli A, Gual P. The mid-infrared spectroscopy: A novel non-invasive diagnostic tool for NASH diagnosis in severe obesity. JHEP Rep 2019;1:361-8. [PMID: 32039387 DOI: 10.1016/j.jhepr.2019.09.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
201 Albaugh VL, English WJ. What is the impact on the healthcare system if access to bariatric surgery is delayed? Surgery for Obesity and Related Diseases 2017;13:1627-8. [DOI: 10.1016/j.soard.2017.04.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
202 Erstad DJ, Razavi AA, Li S, Tanabe KK, Fuchs BC. Prevention Strategies for Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 255-89. [DOI: 10.1007/978-3-030-21540-8_13] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
203 Yoo ER, Sallam S, Perumpail BJ, Iqbal U, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. When to Initiate Weight Loss Medications in the NAFLD Population. Diseases 2018;6:E91. [PMID: 30274326 DOI: 10.3390/diseases6040091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
204 Conjeevaram Selvakumar PK, Kabbany MN, Alkhouri N. Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. Paediatr Drugs. 2018;20:315-329. [PMID: 29740791 DOI: 10.1007/s40272-018-0292-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
205 Cheung A, Levitsky J. Follow-up of the Post-Liver Transplantation Patient: A Primer for the Practicing Gastroenterologist. Clin Liver Dis. 2017;21:793-813. [PMID: 28987263 DOI: 10.1016/j.cld.2017.06.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
206 Walle P, Takkunen M, Männistö V, Vaittinen M, Käkelä P, Ågren J, Schwab U, Lindström J, Tuomilehto J, Uusitupa M, Pihlajamäki J. Alterations in fatty acid metabolism in response to obesity surgery combined with dietary counseling. Nutr Diabetes 2017;7:e285. [PMID: 28869586 DOI: 10.1038/nutd.2017.33] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
207 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Lonardo A. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. Adv Ther 2016;33:291-319. [DOI: 10.1007/s12325-016-0306-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 10.6] [Reference Citation Analysis]
208 Plaza-Díaz J, Solis-Urra P, Aragón-Vela J, Rodríguez-Rodríguez F, Olivares-Arancibia J, Álvarez-Mercado AI. Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. Biomedicines 2021;9:145. [PMID: 33546191 DOI: 10.3390/biomedicines9020145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
209 Armandi A, Schattenberg JM. Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches. Nutrients 2021;13:1977. [PMID: 34201382 DOI: 10.3390/nu13061977] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
210 Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18:151-166. [PMID: 33128017 DOI: 10.1038/s41575-020-00372-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 46] [Article Influence: 31.0] [Reference Citation Analysis]
211 Caussy C. Should We Screen High-Risk Populations for NAFLD? Curr Hepatology Rep 2019;18:433-43. [DOI: 10.1007/s11901-019-00497-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
212 Verbeek J, Jacobs A, Spincemaille P, Cassiman D. Development of a Representative Mouse Model with Nonalcoholic Steatohepatitis. Curr Protoc Mouse Biol 2016;6:201-10. [PMID: 27248435 DOI: 10.1002/cpmo.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
213 Nelson SM, Hoskins JD, Lisanti C, Chaudhuri J. Ultrasound Fatty Liver Indicator: A Simple Tool for Differentiating Steatosis From Nonalcoholic Steatohepatitis: Validity in the Average Obese Population. J Ultrasound Med 2020;39:749-59. [PMID: 31647137 DOI: 10.1002/jum.15154] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
214 Ledoux S, Sami O, Calabrese D, Le Gall M, Flamant M, Coupaye M. Gastric bypass specifically impairs liver parameters as compared with sleeve gastrectomy, independently of evolution of metabolic disorders. Surgery for Obesity and Related Diseases 2019;15:220-6. [DOI: 10.1016/j.soard.2018.10.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
215 Afonso MB, Castro RE, Rodrigues CMP. Processes exacerbating apoptosis in non-alcoholic steatohepatitis. Clin Sci (Lond) 2019;133:2245-64. [PMID: 31742325 DOI: 10.1042/CS20190068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
216 von Schönfels W, Beckmann JH, Ahrens M, Hendricks A, Röcken C, Szymczak S, Hampe J, Schafmayer C. Histologic improvement of NAFLD in patients with obesity after bariatric surgery based on standardized NAS (NAFLD activity score). Surg Obes Relat Dis 2018;14:1607-16. [PMID: 30146425 DOI: 10.1016/j.soard.2018.07.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 10.7] [Reference Citation Analysis]
217 Wan T, Köhn N, Kröll D, Berzigotti A. Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study. Obes Surg 2021;31:702-11. [PMID: 32959331 DOI: 10.1007/s11695-020-04971-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
218 Ivanics T, Abreu P, De Martin E, Sapisochin G. Changing Trends in Liver Transplantation: Challenges and Solutions. Transplantation 2021;105:743-56. [PMID: 32910093 DOI: 10.1097/TP.0000000000003454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
219 Sampath K, Dinani AM, Rothstein RI. Endoscopic Devices for Obesity. Curr Obes Rep 2016;5:251-61. [PMID: 27115879 DOI: 10.1007/s13679-016-0217-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
220 Schwarz AC, Billeter AT, Scheurlen KM, Blüher M, Müller-Stich BP. Comorbidities as an Indication for Metabolic Surgery. Visc Med 2018;34:381-7. [PMID: 30498706 DOI: 10.1159/000493291] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
221 Ssentongo P, Ssentongo AE, Dykes T, Pauli EM, Soybel DI. Nonalcoholic Fatty Liver Disease as a High-Value Predictor of Postoperative Hyperglycemia and Its Associated Complications in Major Abdominal Surgery. Journal of the American College of Surgeons 2018;227:419-429.e6. [DOI: 10.1016/j.jamcollsurg.2018.07.655] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
222 Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH epidemic: A call to action. Obesity (Silver Spring) 2021;29:1401-12. [PMID: 34365735 DOI: 10.1002/oby.23250] [Reference Citation Analysis]
223 Ratziu V, Ghabril M, Romero-Gomez M, Svegliati-Baroni G. Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. Transplantation 2019;103:28-38. [PMID: 30300289 DOI: 10.1097/TP.0000000000002483] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
224 Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:221-35. [PMID: 33317243 DOI: 10.3350/cmh.2020.0239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
225 Ooi GJ, Burton PR, Bayliss J, Raajendiran A, Earnest A, Laurie C, Kemp WW, Mclean CA, Roberts SK, Watt MJ, Brown WA. Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study. OBES SURG 2019;29:99-108. [DOI: 10.1007/s11695-018-3479-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
226 Lin C, Kohli R. Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease. Curr Gastroenterol Rep 2020;22. [DOI: 10.1007/s11894-020-00786-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
227 Lan T, Yu Y, Zhang J, Li H, Weng Q, Jiang S, Tian S, Xu T, Hu S, Yang G, Zhang Y, Wang W, Wang L, Zhu Q, Rong X, Guo J. Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP-Activated Protein Kinase Signaling Pathway. Hepatology 2021;74:686-703. [PMID: 33576035 DOI: 10.1002/hep.31749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
228 Duarte SMB, Stefano JT, Vanni DS, Carrilho FJ, Oliveira CPMS. IMPACT OF CURRENT DIET AT THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). Arq Gastroenterol 2019;56:431-9. [PMID: 31721969 DOI: 10.1590/S0004-2803.201900000-67] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
229 Kannt A, Papada E, Kammermeier C, D'Auria G, Jiménez-Hernández N, Stephan M, Schwahn U, Madsen AN, Østergaard MV, Dedoussis G, Francino MP; MAST4HEALTH consortium. Mastiha (Pistacia lentiscus) Improves Gut Microbiota Diversity, Hepatic Steatosis, and Disease Activity in a Biopsy-Confirmed Mouse Model of Advanced Non-Alcoholic Steatohepatitis and Fibrosis. Mol Nutr Food Res 2019;63:e1900927. [PMID: 31599067 DOI: 10.1002/mnfr.201900927] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
230 NtandjaWandji LC, Baud G, Lassailly G. [What is the position of bariatric surgery in the treatment of non-alcoholic steatohepatitis?]. Presse Med 2019;48:1502-6. [PMID: 31757736 DOI: 10.1016/j.lpm.2019.09.016] [Reference Citation Analysis]
231 López IC, Aroca FG, Bernal MDF, Mompeán JAL, Bernal ÁB, Martínez AMH, Barba EM, Velasco JAN, Paricio PP. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease. Obes Surg 2017;27:2347-53. [PMID: 28229316 DOI: 10.1007/s11695-017-2606-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
232 Eslam M, George J. Genetic and epigenetic mechanisms of NASH. Hepatol Int 2016;10:394-406. [PMID: 26683320 DOI: 10.1007/s12072-015-9689-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
233 Jacobs A, Warda A, Verbeek J, Cassiman D, Spincemaille P. An Overview of Mouse Models of Nonalcoholic Steatohepatitis: From Past to Present. Current Protocols in Mouse Biology 2016;6:185-200. [DOI: 10.1002/cpmo.3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
234 Ichikawa H, Imoto H, Tanaka N, Fujishima F, Tsuchiya T, Watanabe K, Aoki T, Kohyama A, Morikawa T, Ohnuma S, Naitoh T, Kamei T, Unno M. The role of bilio-pancreatic limb in nonalcoholic steatohepatitis improvement after duodenal-jejunal bypass in rats. Surgery 2021:S0039-6060(21)00679-6. [PMID: 34389163 DOI: 10.1016/j.surg.2021.07.003] [Reference Citation Analysis]
235 Issa D, Wattacheril J, Sanyal AJ. Treatment options for nonalcoholic steatohepatitis - a safety evaluation. Expert Opin Drug Saf. 2017;16:903-913. [PMID: 28641031 DOI: 10.1080/14740338.2017.1343299] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
236 Jirapinyo P, Thompson CC. Treatment of NASH with Gastric Bypass. Curr Gastroenterol Rep 2018;20. [DOI: 10.1007/s11894-018-0653-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
237 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
238 Iqbal Z, Fachim HA, Gibson JM, Baricevic-Jones I, Campbell AE, Geary B, Donn RP, Hamarashid D, Syed A, Whetton AD, Soran H, Heald AH. Changes in the Proteome Profile of People Achieving Remission of Type 2 Diabetes after Bariatric Surgery. J Clin Med 2021;10:3659. [PMID: 34441954 DOI: 10.3390/jcm10163659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021:gutjnl-2020-323202. [PMID: 33632710 DOI: 10.1136/gutjnl-2020-323202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
240 Prabhakar O, Bhuvaneswari M. Role of diet and lifestyle modification in the management of nonalcoholic fatty liver disease and type 2 diabetes. Tzu Chi Med J 2021;33:135-45. [PMID: 33912410 DOI: 10.4103/tcmj.tcmj_86_20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
241 Wilson R, Aminian A, Tahrani AA. Metabolic surgery: A clinical update. Diabetes Obes Metab 2021;23 Suppl 1:63-83. [PMID: 33621412 DOI: 10.1111/dom.14235] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Nudel J, Sanchez VM. Surgical management of obesity. Metabolism 2019;92:206-16. [PMID: 30576688 DOI: 10.1016/j.metabol.2018.12.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
243 Hendley MA, Isely C, Murphy KP, Hall HE, Annamalai P, Gower RM. Scaffold Implant Into the Epididymal Adipose Tissue Protects Mice From High Fat Diet Induced Ectopic Lipid Accumulation and Hyperinsulinemia. Front Bioeng Biotechnol 2020;8:562. [PMID: 32612981 DOI: 10.3389/fbioe.2020.00562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Zakka K, Chidambaram S, Mansour S, Mahawar K, Salminen P, Almino R, Schauer P, Kinross J, Purkayastha S; PanSurg Collaborative. SARS-CoV-2 and Obesity: "CoVesity"-a Pandemic Within a Pandemic. Obes Surg 2021;31:1745-54. [PMID: 33479921 DOI: 10.1007/s11695-020-04919-0] [Reference Citation Analysis]
245 Loomba R, Lim JK, Patton H, El-Serag HB. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2020;158:1822-30. [PMID: 32006545 DOI: 10.1053/j.gastro.2019.12.053] [Cited by in Crossref: 49] [Cited by in F6Publishing: 60] [Article Influence: 49.0] [Reference Citation Analysis]
246 Clarembeau F, Bale G, Lanthier N. Cirrhosis and insulin resistance: current knowledge, pathophysiological mechanisms, complications and potential treatments. Clin Sci (Lond) 2020;134:2117-35. [PMID: 32820802 DOI: 10.1042/CS20200022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
247 Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00112. [PMID: 33102794 DOI: 10.1002/edm2.112] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
248 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016;59:1121-40. [DOI: 10.1007/s00125-016-3902-y] [Cited by in Crossref: 206] [Cited by in F6Publishing: 186] [Article Influence: 41.2] [Reference Citation Analysis]
249 Lavín-Alconero L, Fernández-Lanas T, Iruzubieta-Coz P, Arias-Loste MT, Rodriguez-Duque JC, Rivas C, Cagigal ML, Montalbán C, Useros AL, Álvarez-Cancelo A, García-Saiz M, Crespo-García J. Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study). Trials 2021;22:756. [PMID: 34717726 DOI: 10.1186/s13063-021-05695-7] [Reference Citation Analysis]
250 Lefebvre P, Lalloyer F, Baugé E, Pawlak M, Gheeraert C, Dehondt H, Vanhoutte J, Woitrain E, Hennuyer N, Mazuy C, Bobowski-Gérard M, Zummo FP, Derudas B, Driessen A, Hubens G, Vonghia L, Kwanten WJ, Michielsen P, Vanwolleghem T, Eeckhoute J, Verrijken A, Van Gaal L, Francque S, Staels B. Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin. JCI Insight 2017;2:92264. [PMID: 28679947 DOI: 10.1172/jci.insight.92264] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 12.3] [Reference Citation Analysis]
251 Viganò L, Lleo A, Aghemo A. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma-a composite scenario. Hepatobiliary Surg Nutr 2018;7:130-3. [PMID: 29744343 DOI: 10.21037/hbsn.2018.01.01] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
252 Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016;13:196-205. [PMID: 26907882 DOI: 10.1038/nrgastro.2016.3] [Cited by in Crossref: 150] [Cited by in F6Publishing: 144] [Article Influence: 30.0] [Reference Citation Analysis]
253 VanWagner LB, Khan SS, Ning H, Siddique J, Lewis CE, Carr JJ, Vos MB, Speliotes E, Terrault NA, Rinella ME, Lloyd-Jones DM, Allen NB. Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. Liver Int 2018;38:706-14. [PMID: 28963767 DOI: 10.1111/liv.13603] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
254 Mellinger JL, Shedden K, Winder GS, Fernandez AC, Lee BP, Waljee J, Fontana R, Volk ML, Blow FC, Lok ASF. Bariatric surgery and the risk of alcohol-related cirrhosis and alcohol misuse. Liver Int 2021;41:1012-9. [PMID: 33529460 DOI: 10.1111/liv.14805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
255 Van Gaal LF, Mertens J, Francque S, De Block C. Therapeutic approaches for non-alcoholic steatohepatitis. Ther Adv Endocrinol Metab 2021;12:20420188211034300. [PMID: 34497708 DOI: 10.1177/20420188211034300] [Reference Citation Analysis]
256 Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K, Busetto L, Frühbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek GH, Vinker S, Ungan M, Mendive JM, Lionis C. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021;3:100322. [PMID: 34693236 DOI: 10.1016/j.jhepr.2021.100322] [Reference Citation Analysis]
257 Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, Xue H, Liu Y, Zhang Y. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne) 2021;12:721135. [PMID: 34497589 DOI: 10.3389/fendo.2021.721135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
258 Codjia T, Rebibo L, François A, Lagnel C, Huet E, Bekri S, Pattou F, Régimbeau JM, Schwarz L. Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study. Obes Surg 2021;31:3548-56. [PMID: 33844174 DOI: 10.1007/s11695-021-05402-0] [Reference Citation Analysis]
259 Souto KP, Meinhardt NG, Ramos MJ, Ulbrich-kulkzynski JM, Stein AT, Damin DC. Nonalcoholic fatty liver disease in patients with different baseline glucose status undergoing bariatric surgery: analysis of intraoperative liver biopsies and literature review. Surgery for Obesity and Related Diseases 2018;14:66-73. [DOI: 10.1016/j.soard.2017.09.527] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
260 Vallet-Pichard A, Parlati L, Pol S. [Epidemiology of non-alcoholic steatohepatitis. Extent/burden of the problem and its impact on public health]. Presse Med 2019;48:1459-67. [PMID: 31757728 DOI: 10.1016/j.lpm.2019.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
261 Mumtaz K, Lipshultz H, Jalil S, Porter K, Li N, Kelly SG, Conteh LF, Michaels A, Hanje J, Black S, Hussan H. Bariatric Surgery in Patients with Cirrhosis: Careful Patient and Surgery-Type Selection Is Key to Improving Outcomes. Obes Surg 2020;30:3444-52. [PMID: 32285332 DOI: 10.1007/s11695-020-04583-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
262 Martins E, Oliveira A. NAFLD and cardiovascular disease. Porto Biomed J 2018;3:e2. [PMID: 31595238 DOI: 10.1016/j.pbj.0000000000000002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
263 Wang G, Wang Q, Bai J, Li G, Tao K, Wang G, Xia Z. RYGB increases postprandial gastric nesfatin-1 and rapid relieves NAFLD via gastric nerve detachment. PLoS One 2020;15:e0243640. [PMID: 33301513 DOI: 10.1371/journal.pone.0243640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020;323:1175-1183. [PMID: 32207804 DOI: 10.1001/jama.2020.2298] [Cited by in Crossref: 119] [Cited by in F6Publishing: 121] [Article Influence: 119.0] [Reference Citation Analysis]
265 Boursier J, Diehl AM. Nonalcoholic Fatty Liver Disease and the Gut Microbiome. Clin Liver Dis 2016;20:263-75. [PMID: 27063268 DOI: 10.1016/j.cld.2015.10.012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 8.3] [Reference Citation Analysis]
266 Crane JD, Mcgowan BM. Clinical Assessment of the Patient with Overweight or Obesity. In: Vitti P, Hegedus L, editors. Thyroid Diseases. Cham: Springer International Publishing; 2017. pp. 1-27. [DOI: 10.1007/978-3-319-47685-8_19-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
267 Zoubek ME, Trautwein C, Strnad P. Reversal of liver fibrosis: From fiction to reality. Best Practice & Research Clinical Gastroenterology 2017;31:129-41. [DOI: 10.1016/j.bpg.2017.04.005] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 16.8] [Reference Citation Analysis]
268 Romero FA, Jones CT, Xu Y, Fenaux M, Halcomb RL. The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. J Med Chem 2020;63:5031-73. [PMID: 31930920 DOI: 10.1021/acs.jmedchem.9b01701] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 29.0] [Reference Citation Analysis]
269 Salman MA, Salman AA, Abdelsalam A, Atallah M, Shaaban HE, El-Mikkawy A, Omar MG, Elshenoufy M. Laparoscopic Sleeve Gastrectomy on the Horizon as a Promising Treatment Modality for NAFLD. Obes Surg 2020;30:87-95. [PMID: 31372873 DOI: 10.1007/s11695-019-04118-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
270 Kaufmann B, Reca A, Wang B, Friess H, Feldstein AE, Hartmann D. Mechanisms of nonalcoholic fatty liver disease and implications for surgery. Langenbecks Arch Surg 2021;406:1-17. [PMID: 32833053 DOI: 10.1007/s00423-020-01965-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
271 Blanchard C, Ledoux S, Verhaegen A, Wargny M, Letessier E, Stepanian A, Huten N, Jacobi D, Krempf M, Le Bras M, Perrocheau Guillouche M, Arnaud L, Pichelin M, Van Gaal L, Cariou B, Le May C. Roux-en-Y gastric bypass, but not sleeve gastrectomy, decreases plasma PCSK9 levels in morbidly obese patients. Diabetes Metab 2020;46:480-7. [PMID: 32032671 DOI: 10.1016/j.diabet.2020.01.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
272 Motomura T, Amirneni S, Diaz-Aragon R, Faccioli LAP, Malizio MR, Coard MC, Kocas-Kilicarslan ZN, Frau C, Haep N, Ostrowska A, Florentino RM, Soto-Gutierrez A. Is HSD17B13 Genetic Variant a Protector for Liver Dysfunction? Future Perspective as a Potential Therapeutic Target. J Pers Med 2021;11:619. [PMID: 34208839 DOI: 10.3390/jpm11070619] [Reference Citation Analysis]
273 Ali AH, Petroski GF, Diaz-Arias AA, Al Juboori A, Wheeler AA, Ganga RR, Pitt JB, Spencer NM, Hammoud GM, Rector RS, Parks EJ, Ibdah JA. A Model Incorporating Serum Alkaline Phosphatase for Prediction of Liver Fibrosis in Adults with Obesity and Nonalcoholic Fatty Liver Disease. J Clin Med 2021;10:3311. [PMID: 34362095 DOI: 10.3390/jcm10153311] [Reference Citation Analysis]
274 Mechanick JI, Apovian C, Brethauer S, Garvey WT, Joffe AM, Kim J, Kushner RF, Richard Lindquist, Pessah-pollack R, Seger J, Urman RD, Adams S, Cleek JB, Correa R, Figaro MK, Flanders K, Grams J, Hurley DL, Kothari S, Seger MV, Still CD. Clinical Practice Guidelines For The Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 Update: Cosponsored By American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society For Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Endocrine Practice 2019;25:1-75. [DOI: 10.4158/gl-2019-0406] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 19.5] [Reference Citation Analysis]
275 Chen MM, Cai JJ, Yu Y, She ZG, Li H. Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment. Gene Expr 2019;19:175-85. [PMID: 30940296 DOI: 10.3727/105221619X15536120524171] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
276 Patel YA, Gifford EJ, Glass LM, Turner MJ, Han B, Moylan CA, Choi S, Suzuki A, Provenzale D, Hunt CM. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. Dig Dis Sci 2018;63:2259-66. [DOI: 10.1007/s10620-018-5123-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
277 Coccia F, Testa M, Guarisco G, Di Cristofano C, Silecchia G, Leonetti F, Gastaldelli A, Capoccia D. Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD. Nutr Metab Cardiovasc Dis 2020;30:106-13. [PMID: 31677889 DOI: 10.1016/j.numecd.2019.08.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
278 Mendoza YP, Becchetti C, Watt KD, Berzigotti A. Risks and Rewards of Bariatric Surgery in Advanced Chronic Liver Diseases. Semin Liver Dis 2021. [PMID: 34243194 DOI: 10.1055/s-0041-1731705] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
279 Behari J, Graham L, Wang R, Schirda C, Borhani AA, Methé BA, Li K, Morris A, Luu HN, Palmieri S, Yuan JM. Dynamics of hepatic steatosis resolution and changes in gut microbiome with weight loss in nonalcoholic fatty liver disease. Obes Sci Pract 2021;7:217-25. [PMID: 33841891 DOI: 10.1002/osp4.476] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
280 Azulai S, Grinbaum R, Beglaibter N, Eldar SM, Rubin M, Carmi S, Ben-Haroush Schyr R, Romano-Zelekha O, Ben-Zvi D. Bariatric Surgery Affects Plasma Levels of Alanine Aminotransferase Independent of Weight Loss: A Registry-Based Study. J Clin Med 2021;10:2724. [PMID: 34203100 DOI: 10.3390/jcm10122724] [Reference Citation Analysis]
281 Kim KS, Lee BW, Kim YJ, Lee DH, Cha BS, Park CY. Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment. Diabetes Metab J 2019;43:127-43. [PMID: 30993937 DOI: 10.4093/dmj.2019.0034] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 19.0] [Reference Citation Analysis]
282 Nawrot M, Peschard S, Lestavel S, Staels B. Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. Metabolism 2021;123:154844. [PMID: 34343577 DOI: 10.1016/j.metabol.2021.154844] [Reference Citation Analysis]
283 Laferrère B, Pattou F. Weight-Independent Mechanisms of Glucose Control After Roux-en-Y Gastric Bypass. Front Endocrinol (Lausanne) 2018;9:530. [PMID: 30250454 DOI: 10.3389/fendo.2018.00530] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
284 Nobili V, Carpino G, De Peppo F, Caccamo R, Mosca A, Romito I, Overi D, Franchitto A, Onori P, Alisi A, Gaudio E. Laparoscopic Sleeve Gastrectomy Improves Nonalcoholic Fatty Liver Disease-Related Liver Damage in Adolescents by Reshaping Cellular Interactions and Hepatic Adipocytokine Production. J Pediatr 2018;194:100-108.e3. [PMID: 29198531 DOI: 10.1016/j.jpeds.2017.10.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
285 Tacke F, Weiskirchen R. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Ann Transl Med 2021;9:729. [PMID: 33987427 DOI: 10.21037/atm-20-4354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
286 Frey S, Patouraux S, Debs T, Gugenheim J, Anty R, Iannelli A. Prevalence of NASH/NAFLD in people with obesity who are currently classified as metabolically healthy. Surg Obes Relat Dis 2020;16:2050-7. [PMID: 32788075 DOI: 10.1016/j.soard.2020.07.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
287 Mathews SE, Kumar RB, Shukla AP. Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction: . Current Opinion in Endocrinology & Diabetes and Obesity 2018;25:315-20. [DOI: 10.1097/med.0000000000000432] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
288 Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients 2017;9:E387. [PMID: 28420094 DOI: 10.3390/nu9040387] [Cited by in Crossref: 166] [Cited by in F6Publishing: 139] [Article Influence: 41.5] [Reference Citation Analysis]
289 Krawczyk M, Jiménez-Agüero R, Alustiza JM, Emparanza JI, Perugorria MJ, Bujanda L, Lammert F, Banales JM. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. Surg Obes Relat Dis 2016;12:1838-46. [PMID: 27576208 DOI: 10.1016/j.soard.2016.06.004] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
290 Gerhard GS, Still CD, DiStefano JK. High False-Negative Rate for Nonalcoholic Steatohepatitis in Extreme Obesity. Gastroenterology 2016;150:283-4. [PMID: 26616574 DOI: 10.1053/j.gastro.2015.09.050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
291 Laursen TL, Hagemann CA, Wei C, Kazankov K, Thomsen KL, Knop FK, Grønbæk H. Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. World J Hepatol 2019; 11(2): 138-149 [PMID: 30820265 DOI: 10.4254/wjh.v11.i2.138] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 35.0] [Reference Citation Analysis]
292 Tomkin GH, Owens D. Obesity diabetes and the role of bile acids in metabolism. J Transl Int Med 2016;4:73-80. [PMID: 28191525 DOI: 10.1515/jtim-2016-0018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
293 Castagneto-Gissey L, Casella-Mariolo J, Casella G, Mingrone G. Obesity Surgery and Cancer: What Are the Unanswered Questions? Front Endocrinol (Lausanne) 2020;11:213. [PMID: 32351453 DOI: 10.3389/fendo.2020.00213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
294 Shouhed D, Steggerda J, Burch M, Noureddin M. The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2017;11:797-811. [PMID: 28712339 DOI: 10.1080/17474124.2017.1355731] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
295 Zhang YX, Yang L, Yang CC, Wang WY, Shen JH, Shi ML, Yu Y, Dai QC, Gu Y, Yang JJ, Yu WW, Yao K, Hu M, Ni J, Sun JL, Zhang L, Sun HX, Lu XF, Wang B. Correlation between Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Disease before and after Metabolic Bariatric Surgery. Obes Surg 2020;30:3803-12. [PMID: 32529354 DOI: 10.1007/s11695-020-04696-w] [Reference Citation Analysis]
296 Neuschwander-tetri BA. Future Treatments of NASH. Curr Hepatology Rep 2016;15:125-33. [DOI: 10.1007/s11901-016-0300-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
297 Ooi GJ, Meikle PJ, Huynh K, Earnest A, Roberts SK, Kemp W, Parker BL, Brown W, Burton P, Watt MJ. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. J Hepatol 2021;75:524-35. [PMID: 33887358 DOI: 10.1016/j.jhep.2021.04.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
298 Jamialahmadi T, Nematy M, Bo S, Ponzo V, Jangjoo A, Goshayeshi L, Tasbandi A, Nikiforov NG, Sahebkar A. Associations between Pre-Bariatric High-Sensitivity C-Reactive Protein and Post-Surgery Outcomes. Diagnostics (Basel) 2021;11:721. [PMID: 33919641 DOI: 10.3390/diagnostics11040721] [Reference Citation Analysis]
299 Parker BM, Wu J, You J, Barnes DS, Yerian L, Kirwan JP, Schauer PR, Sessler DI. Reversal of fibrosis in patients with nonalcoholic steatohepatosis after gastric bypass surgery. BMC Obes 2017;4:32. [PMID: 28919979 DOI: 10.1186/s40608-017-0168-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
300 Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells 2020;9:E1638. [PMID: 32650421 DOI: 10.3390/cells9071638] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
301 Luo RB, Suzuki T, Hooker JC, Covarrubias Y, Schlein A, Liu S, Schwimmer JB, Reeder SB, Funk LM, Greenberg JA, Campos GM, Sandler BJ, Horgan S, Sirlin CB, Jacobsen GR. How bariatric surgery affects liver volume and fat density in NAFLD patients. Surg Endosc 2018;32:1675-82. [PMID: 29218660 DOI: 10.1007/s00464-017-5846-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
302 Manco M, Mosca A, De Peppo F, Caccamo R, Cutrera R, Giordano U, De Stefanis C, Alisi A, Baumann U, Silecchia G, Nobili V. The Benefit of Sleeve Gastrectomy in Obese Adolescents on Nonalcoholic Steatohepatitis and Hepatic Fibrosis. The Journal of Pediatrics 2017;180:31-37.e2. [DOI: 10.1016/j.jpeds.2016.08.101] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 15.0] [Reference Citation Analysis]
303 Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant waitlisting in the era of direct-acting antiviral therapy. Hepatology. 2017;65:804-812. [PMID: 28012259 DOI: 10.1002/hep.28923] [Cited by in Crossref: 147] [Cited by in F6Publishing: 126] [Article Influence: 29.4] [Reference Citation Analysis]
304 Singh T, Kochhar GS, Goh GB, Schauer P, Brethauer S, Kroh M, Aminian A, Lopez R, Dasarathy S, McCullough AJ. Safety and efficacy of bariatric surgery in patients with advanced fibrosis. Int J Obes (Lond). 2017;41:443-449. [PMID: 27881858 DOI: 10.1038/ijo.2016.212] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
305 Izzy M, Angirekula M, Abu Dayyeh BK, Bazerbachi F, Watt KD. Bariatric surgery proves long-term benefit in patients with cirrhosis. Gastroenterol Rep (Oxf) 2021;9:252-6. [PMID: 34316375 DOI: 10.1093/gastro/goaa057] [Reference Citation Analysis]
306 Perysinakis I, Pappis HC, Margaris E. Current Controversies in Metabolic Surgery for Nonalcoholic Fatty Liver Disease. OBES SURG 2019;29:1058-67. [DOI: 10.1007/s11695-019-03705-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
307 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-1402. [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004] [Cited by in Crossref: 1478] [Cited by in F6Publishing: 1378] [Article Influence: 295.6] [Reference Citation Analysis]
308 Ooi GJ, Burton PR, Kemp WW, Roberts SK, Brown WA. Reply to "Crashing NASH in Patients Listed for Bariatric Surgery". Obes Surg 2019;29:640-1. [PMID: 30565101 DOI: 10.1007/s11695-018-03638-x] [Reference Citation Analysis]
309 Temple JL, Cordero P, Li J, Nguyen V, Oben JA. A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci 2016;17:E947. [PMID: 27314342 DOI: 10.3390/ijms17060947] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 15.4] [Reference Citation Analysis]
310 Ginès P, Graupera I, Lammert F, Angeli P, Caballeria L, Krag A, Guha IN, Murad SD, Castera L. Screening for liver fibrosis in the general population: a call for action. The Lancet Gastroenterology & Hepatology 2016;1:256-60. [DOI: 10.1016/s2468-1253(16)30081-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 19] [Article Influence: 12.2] [Reference Citation Analysis]
311 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 1978] [Cited by in F6Publishing: 1822] [Article Influence: 494.5] [Reference Citation Analysis]
312 Angelini G, Castagneto-Gissey L, Casella-Mariolo J, Caristo ME, Russo MF, Lembo E, Verrastro O, Stefanizzi G, Marini PL, Casella G, Bornstein SR, Rubino F, Mingrone G. Duodenal-jejunal bypass improves nonalcoholic fatty liver disease independently of weight loss in rodents with diet-induced obesity. Am J Physiol Gastrointest Liver Physiol 2020;319:G502-11. [PMID: 32812775 DOI: 10.1152/ajpgi.00357.2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
313 Targher G, Marchesini G, Byrne CD. Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? Diabetes Metab. 2016;42:142-156. [PMID: 27142870 DOI: 10.1016/j.diabet.2016.04.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 10.2] [Reference Citation Analysis]
314 Calvente CJ, Tameda M, Johnson CD, Del Pilar H, Lin YC, Adronikou N, De Mollerat Du Jeu X, Llorente C, Boyer J, Feldstein AE. Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223. J Clin Invest 2019;129:4091-109. [PMID: 31295147 DOI: 10.1172/JCI122258] [Cited by in Crossref: 49] [Cited by in F6Publishing: 27] [Article Influence: 24.5] [Reference Citation Analysis]
315 Perdomo CM, Garcia-Fernandez N, Escalada J. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate? J Clin Med 2021;10:2040. [PMID: 34068699 DOI: 10.3390/jcm10092040] [Reference Citation Analysis]
316 Mahawar KK, Parmar C, Graham Y, Abouleid A, Carr WRJ, Jennings N, Schroeder N, Small PK. Routine Liver Biopsy During Bariatric Surgery: an Analysis of Evidence Base. OBES SURG 2016;26:177-81. [DOI: 10.1007/s11695-015-1916-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
317 Yoon JH, Lee JM, Kim JH, Lee KB, Kim H, Hong SK, Yi NJ, Lee KW, Suh KS. Hepatic fibrosis grading with extracellular volume fraction from iodine mapping in spectral liver CT. Eur J Radiol 2021;137:109604. [PMID: 33618210 DOI: 10.1016/j.ejrad.2021.109604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
318 Tilg H. How to Approach a Patient With Nonalcoholic Fatty Liver Disease. Gastroenterology 2017;153:345-9. [PMID: 28647352 DOI: 10.1053/j.gastro.2017.06.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
319 Patel SS, Siddiqui MS. Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. Drugs. 2019;79:75-84. [PMID: 30588564 DOI: 10.1007/s40265-018-1040-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
320 Padda J, Khalid K, Khedr A, Tasnim F, Al-Ewaidat OA, Cooper AC, Jean-Charles G. Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus 2021;13:e17321. [PMID: 34557367 DOI: 10.7759/cureus.17321] [Reference Citation Analysis]
321 Carr RM, Oranu A, Khungar V. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. Gastroenterol Clin North Am 2016;45:639-52. [PMID: 27837778 DOI: 10.1016/j.gtc.2016.07.003] [Cited by in Crossref: 89] [Cited by in F6Publishing: 77] [Article Influence: 17.8] [Reference Citation Analysis]
322 Cassard AM, Gérard P, Perlemuter G. Microbiota, Liver Diseases, and Alcohol. Microbiol Spectr 2017;5. [PMID: 28840806 DOI: 10.1128/microbiolspec.BAD-0007-2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
323 Ding L, Fang Z, Liu Y, Zhang E, Huang T, Yang L, Wang Z, Huang W. Targeting Bile Acid-Activated Receptors in Bariatric Surgery. Handb Exp Pharmacol 2019;256:359-78. [PMID: 31144046 DOI: 10.1007/164_2019_229] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
324 Addeo P, Cesaretti M, Anty R, Iannelli A. Liver transplantation for bariatric surgery-related liver failure: a systematic review of a rare condition. Surg Obes Relat Dis 2019;15:1394-401. [PMID: 31285130 DOI: 10.1016/j.soard.2019.06.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
325 Bel Lassen P, Charlotte F, Liu Y, Bedossa P, Le Naour G, Tordjman J, Poitou C, Bouillot JL, Genser L, Zucker JD, Sokolovska N, Aron-Wisnewsky J, Clément K. The FAT Score, a Fibrosis Score of Adipose Tissue: Predicting Weight-Loss Outcome After Gastric Bypass. J Clin Endocrinol Metab 2017;102:2443-53. [PMID: 28419237 DOI: 10.1210/jc.2017-00138] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
326 Younossi Z, Henry L. Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. Gastroenterology. 2016;150:1778-1785. [PMID: 26980624 DOI: 10.1053/j.gastro.2016.03.005] [Cited by in Crossref: 141] [Cited by in F6Publishing: 123] [Article Influence: 28.2] [Reference Citation Analysis]
327 Casimiro I, Sam S, Brady MJ. Endocrine implications of bariatric surgery: a review on the intersection between incretins, bone, and sex hormones. Physiol Rep 2019;7:e14111. [PMID: 31134746 DOI: 10.14814/phy2.14111] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
328 Chitturi S, Wong VW, Chan WK, Wong GL, Wong SK, Sollano J, Ni YH, Liu CJ, Lin YC, Lesmana LA. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. J Gastroenterol Hepatol. 2018;33:86-98. [PMID: 28692197 DOI: 10.1111/jgh.13856] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 27.5] [Reference Citation Analysis]
329 Danin PE, Anty R, Patouraux S, Raucoules-Aimé M, Gugenheim J, Tran A, Gual P, Iannelli A. Non-invasive Evaluation of NAFLD with Indocyanine Green Clearance Test: a Preliminary Study in Morbidly Obese Patients Undergoing Bariatric Surgery. Obes Surg 2018;28:735-42. [PMID: 28875438 DOI: 10.1007/s11695-017-2914-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
330 Shetty A, Syn W. Current treatment options for nonalcoholic fatty liver disease. Current Opinion in Gastroenterology 2019;35:168-76. [DOI: 10.1097/mog.0000000000000528] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
331 Cabré N, Luciano-Mateo F, Baiges-Gayà G, Fernández-Arroyo S, Rodríguez-Tomàs E, Hernández-Aguilera A, París M, Sabench F, Del Castillo D, López-Miranda J, Menéndez JA, Camps J, Joven J. Plasma metabolic alterations in patients with severe obesity and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2020;51:374-87. [PMID: 31825539 DOI: 10.1111/apt.15606] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
332 Yang K, Zhang X, Zhou Y, Chen F, Shen M, Wang Y. Changes in Serum Nesfatin-1 After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Nonalcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes 2020;13:1459-64. [PMID: 32431529 DOI: 10.2147/DMSO.S246281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
333 Wong VW. Current Prevention and Treatment Options for NAFLD. Adv Exp Med Biol 2018;1061:149-57. [PMID: 29956213 DOI: 10.1007/978-981-10-8684-7_12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
334 Lefere S, Stroobant L, Verhelst X, Vanlander A, Berrevoet F, Troisi RI, Van Nieuwenhove Y, Rogiers X, Van Vlierberghe H, Geerts A. Bariatric Surgery Patients Are at Risk for Alcoholic Liver Disease with Need for Liver Transplantation. OBES SURG 2020;30:4659-64. [DOI: 10.1007/s11695-020-04806-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
335 Chakravarthy MV, Waddell T, Banerjee R, Guess N. Nutrition and Nonalcoholic Fatty Liver Disease. Gastroenterology Clinics of North America 2020;49:63-94. [DOI: 10.1016/j.gtc.2019.09.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
336 Frey S, Petrucciani N, Iannelli A. Bariatric Surgery in the Setting of Liver Cirrhosis with Portal Hypertension: the Confection and Particularities of Roux-en-Y Gastric Bypass in a High-Risk Patient. Obes Surg 2020;30:4165-6. [PMID: 32720262 DOI: 10.1007/s11695-020-04715-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
337 Soares GM, Cantelli KR, Balbo SL, Ribeiro RA, Alegre-Maller ACP, Barbosa-Sampaio HC, Boschero AC, Araújo ACF, Bonfleur ML. Liver steatosis in hypothalamic obese rats improves after duodeno-jejunal bypass by reduction in de novo lipogenesis pathway. Life Sci 2017;188:68-75. [PMID: 28866102 DOI: 10.1016/j.lfs.2017.08.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
338 Lucas C, Lucas G, Lucas N, Krzowska-Firych J, Tomasiewicz K. A systematic review of the present and future of non-alcoholic fatty liver disease. Clin Exp Hepatol 2018;4:165-74. [PMID: 30324141 DOI: 10.5114/ceh.2018.78120] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
339 Zamora-Valdes D, Watt KD, Kellogg TA, Poterucha JJ, Di Cecco SR, Francisco-Ziller NM, Taner T, Rosen CB, Heimbach JK. Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy. Hepatology. 2018;68:485-495. [PMID: 29457842 DOI: 10.1002/hep.29848] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 17.0] [Reference Citation Analysis]
340 Hedderich DM, Hasenberg T, Haneder S, Schoenberg SO, Kücükoglu Ö, Canbay A, Otto M. Effects of Bariatric Surgery on Non-alcoholic Fatty Liver Disease: Magnetic Resonance Imaging Is an Effective, Non-invasive Method to Evaluate Changes in the Liver Fat Fraction. OBES SURG 2017;27:1755-62. [DOI: 10.1007/s11695-016-2531-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
341 Chae YJ, Jun DW, Saeed WK, Kang HT, Oh JH, Lee SM, Jang K. Feasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies. J Korean Med Sci 2019;34:e14. [PMID: 30636945 DOI: 10.3346/jkms.2019.34.e14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
342 Greuter T, Malhi H, Gores GJ, Shah VH. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight 2017;2:95354. [PMID: 28878132 DOI: 10.1172/jci.insight.95354] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
343 Karlsson C, Wallenius K, Walentinsson A, Greasley PJ, Miliotis T, Hammar M, Iaconelli A, Tapani S, Raffaelli M, Mingrone G, Carlsson B. Identification of Proteins Associated with the Early Restoration of Insulin Sensitivity After Biliopancreatic Diversion. J Clin Endocrinol Metab 2020;105:dgaa558. [PMID: 32830851 DOI: 10.1210/clinem/dgaa558] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
344 Hartl L, Elias J, Prager G, Reiberger T, Unger LW. Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. World J Gastroenterol 2021; 27(19): 2281-2298 [PMID: 34040322 DOI: 10.3748/wjg.v27.i19.2281] [Reference Citation Analysis]
345 Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68:361-371. [PMID: 29222911 DOI: 10.1002/hep.29724] [Cited by in Crossref: 161] [Cited by in F6Publishing: 144] [Article Influence: 53.7] [Reference Citation Analysis]
346 Tomasiewicz K, Flisiak R, Halota W, Jaroszewicz J, Lebensztejn D, Lisik W, Małkowski P, Pawłowska M, Piekarska A, Simon K, Tronina O; Recommendations of the Polish Group of Experts for Non-Alcoholic Fatty Liver Disease (PGE-NAFLD). Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). Clin Exp Hepatol 2018;4:153-7. [PMID: 30324139 DOI: 10.5114/ceh.2018.78118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
347 Mechanick JI, Apovian C, Brethauer S, Garvey WT, Joffe AM, Kim J, Kushner RF, Lindquist R, Pessah-Pollack R, Seger J, Urman RD, Adams S, Cleek JB, Correa R, Figaro MK, Flanders K, Grams J, Hurley DL, Kothari S, Seger MV, Still CD. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis 2020;16:175-247. [PMID: 31917200 DOI: 10.1016/j.soard.2019.10.025] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 34.5] [Reference Citation Analysis]